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Neonatal mortality accounts for almost half of deaths in children under age five 
worldwide. Etiologic agents of neonatal infection are difficult to identify due to non-specific 
symptoms. We conducted a secondary analysis of data from the Aetiology of Neonatal Infections 
in South Asia (ANISA) cohort to describe the spectrum of infectious etiologies of acute neonatal 
illness and assessed association of individual clinical signs with bacterial versus viral 
infection.Ureaplasma infections typically affect pregnant women and very preterm infants.  
Unexpectedly, Ureaplasma was a leading cause of infection among young infants in ANISA. We 
present and evaluate alternative explanations for this finding. 
We applied a partial latent class Bayesian model (pLCM) using a Gibbs sampler to 
estimate the prevalence of 27 pathogens detectable on a molecular polymerase chain reaction 
(PCR) platform in sick young infants. We estimated prevalence in different subsets of infants 
meeting three WHO case definitions  We calculated the prevalence for common danger signs 
among infants meeting the clinical severe case definition. We used observed diagnostic and 
pLCM results from ANISA to present and evaluate potential alternative explanations of the 
Ureaplasma finding.   
Proportion of illness attributable to bacterial infection was 33%, 14%, and 9% among 
infants in the highest to lowest severity illness WHO case definitions.  Among specimens that 
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tested positive for Ureaplasma, 93% speciated to U. parvum or U. urealyticum.  Ureaplasma test 
results did not possess any of the documented criteria that impact the reliability of pLCM model 
estimates.  Ureaplasma attribution was twice as high among infants who died (15%) when 
compared to infants who survived (7%) (P-value <0.0001). 
Clinical criteria do not clearly differentiate bacterial from viral etiology among young 
infants with possible severe infection.  Given the fact that Ureaplasma is present in term infants, 
and the fact that we did not identify another viable explanation for the ANISA Ureaplasma 
finding, it is plausible to suggest Ureaplasma has been under-detected in previous etiology 
studies. Further research into Ureaplasma as a causative agent of illness in neonateswould 
inform whether changes to current antibiotic regimens recommended by WHO for treatment of 
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CHAPTER 1: SPECIFIC AIMS 
Neonatal mortality accounts for almost 40% of under-five child deaths worldwide. 1-6 
More than a third of neonatal deaths occur in Bangladesh, India, and Pakistan; severe infections 
are among the leading causes.  Neonates with suspected infection are difficult to evaluate due to 
non-specific symptoms and limited diagnostic capabilities.  Young infants are often assessed, 
either by physicians or community health workers using the World Health Organization (WHO) 
Young Infant Integrated Management of Childhood Illnesses (IMCI) possible serious bacterial 
infection (pSBI) clinical algorithm. 7-10  The pSBI case definition was designed using limited 
etiologic data to be sensitive rather than specific to minimize missed opportunities for 
intervention.  However, it results in hospitalization and treatment (a recommended 10 day course 
of injection or intravenous antibiotics) of some infants without serious infection, and presents 
implementation challenges in settings where hospital referral is commonly refused. 
New evidence that simplified home treatment regimens including reduced antibiotic 
injections are effective when hospitalization was refused, and supporting limited oral antibiotic 
treatment of young infants with fast breathing as their only sign, formed the basis of revised 
guidelines and case definitions in 2015.  The guidelines further stratified infants meeting the 
pSBI case definition into a more severe (“critically ill”) and less severe (“clinical severe 
infection”) case definitions.  The critically ill infants are now recommended aggressive antibiotic 
treatment in a hospital setting after receiving pre-referral antibiotic treatment, while the clinical 
severe cases are recommended simpler antibiotic regimens when referral to a hospital is not 
possible.  Lastly, the infants with late onset illness (=>3 days and < 59 days) with isolated fast 
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breathing are recommended to receive oral antibiotic treatment with no hospital referral.  Much 
of the evidence used to inform these guidelines was graded as low quality evidence, and a key 
data gap was comprehensive diagnostic evaluation of infants in the different case strata to allow 
for a link between infectious etiologies and clinical management recommendations. 
One of the key findings from the ANISA study was a high proportion of Ureaplasma spp. 
infections among the infants that met the pSBI case definition. It was the second highest 
proportion estimated of any pathogen in the study.  While Ureaplasma spp. is a known relevant 
infection for neonates, and in particular extremely and very preterm neonates, this finding was 
unexpected.  Here we used the ANISA observed and modeled etiology results to describe 
Ureaplasma as a cause of infection in neonates.  We present and evaluate potential alternative 
explanations of the ANISA Ureaplasma finding, and characterized demographics and clinical 
presentation of infants with infection attributable to Ureaplasma. 
We used a cohort of more than 5000 possible serious infection cases from South Asia 
(the Aetiology of Neonatal Infections or ANISA cohort) with diagnostic testing results for 
bacteria and viruses in blood and respiratory samples to describe the proportion of infants with 
infectious etiologies of their illness with each of the IMCI danger signs.  We will also evaluate 
the etiologic spectrum represented by the revised case definitions for critically ill children, those 
with clinical severe infection, and those with fast breathing as their only clinical sign in the late 
onset period in Bangladesh.  Lastly, we will investigate the ANISA Ureaplasma finding, and 
characterize demographics and clinical presentation of infants with infection attributable to 
Ureaplasma. 
Specific aim #1a:  Describe the distribution of Integrated Management of Childhood 
Illness Case definitions clinical signs among the infants from the ANISA cohort with infectious 
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etiologies.  We will use the posterior probabilities from the parent study etiology model to 
calculate the distribution of clinical signs among the infants who had an identifiable infectious 
etiology, using the Basic Bayesian formula.   
Objective:  Ascertain if there are differences in the distribution of clinical danger signs 
among those infants who had a known infectious etiology of their illness. 
Hypothesis: The distribution of clinical signs among those with an infectious etiology in 
the ANISA study will have a different distribution when compared with cases with no identified 
infectious etiology. 
Specific aim #1b: Evaluation of etiologies captured by Integrated Management of 
Childhood Illness Case definitions for neonatal infections.  We will use a Bayesian partial latent 
class model using a Gibbs sampler to estimate the individual and population level proportions for 
each pathogen under study in the original ANISA cohort who met the clinically severe case 
definition, the first case definition under evaluation.  Additionally, we will estimate the pathogen 
proportions among those that meet the critically ill case definition when compared with the 
clinically severe group, and estimate the pathogen proportions for those infants with fast 
breathing as their only sign in the late onset period (>7 days) when compared with the clinically 
severe group, in the Bangladesh site only.  We will empirically assess the change by looking for 
confidence interval overlap.   
Objective:  Provide evidence that the WHO revisions to the case definitions for possible 
serious infection in neonates are sound. 
Hypotheses: Infants with a clinical severe infection will show similar proportions of 
infectious etiologies as cases meeting the ANISA case definition.  Critically ill infants will have 
a higher proportion of infectious etiologies when compared with clinical severe cases.  Infants 
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with fast breathing as a single sign in the late onset period (7-59 days) will show similar or lower 
proportions of infectious etiologies when compared with clinical severe cases in Bangladesh.  
Specific aim #2:  Understand the demographic characteristics and risk factors associated 
with Ureaplasma spp. infection in neonates in this population of infants in South Asia.  We will 
use the observed diagnostic results data and the partial latent class Bayesian model (pLCM) 
results from the primary ANISA etiology study to present and evaluate potential alternative 
explanations for why Ureaplasma was the second most prevalent etiology of illness in the 
ANISA population.  We seek to characterize infants with infection attributable to Ureaplasma by 
calculating the prevalence of selected demographics and clinical variables of interest using the 
standard Bayesian formula, stratified by preterm vs term and early and late onset of disease. 
Objective:  Describe the infant population with illness attributed to Ureaplasma spp., and 
present and evaluate potential alternative explanations of the ANISA Ureaplasma finding.   
Hypothesis:  There will be no other viable explanation for the Ureaplasma finding, and it 
is plausible to suggest that Ureaplasma has been under detected in previous etiology studies. 
5 
CHAPTER 2: BACKGROUND 
Most developing countries have witnessed substantial declines in mortality among 
children <5 years of age  5 11. In contrast, neonatal mortality rates have remained relatively 
consistent, with an estimated 3.6 million annual neonatal deaths globally11-1314,15.  Neonatal 
mortality accounts for about 40-50% of under-five child deaths. 14-16 Neonatal infections, 
including sepsis, pneumonia and meningitis account for an estimated 1.4 million neonatal deaths 
worldwide every year. 6,13 About 60% of the deaths due to infections occur in the first week of 
life,1 and therefore, there is only a narrow window of opportunity to intervene. The risk of death 
in the second month of life is also high, and a vast majority of these deaths occur in the poorest 
countries of Asia and Africa. 4 Three South Asian countries, Bangladesh, India and Pakistan, 
account for more than a third of all global neonatal deaths, and a disproportionate portion of 
deaths in the second month of life. 17,18 The proportion of all child <5 deaths in South Asia 
increased from 45% to 57% between 1990 and 2015. 17 The majority of births and deaths in these 
countries occur at home. 19-26A variety of preventive approaches, including maternal 
immunization 27, clean childbirth practices, emollient therapy 28,29, promotion of exclusive 
breastfeeding, and chlorhexidine cord cleansing 30 hold promise in reducing the total number of 
infection-related young infant deaths. In addition, other investigators have demonstrated the 
feasibility and effectiveness of identifying young infants with serious infection using clinical 
algorithms, and safely treating them at the community level. 8,10,13,31-33  
Several antibiotic regimens are currently used to treat young infant infections and other 
regimens are under evaluation. 34 33 Most treatments, however, are presumptive and the diagnosis 
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is based on clinical algorithms which are not specific for invasive bacterial infection. 9,34,35 
Although treatment regimens currently utilized can reduce neonatal mortality by up to 50% 
13,31,33,36, appropriate formulation of antibiotic treatment regimens is hampered by lack of data on 
etiology and antibiotic susceptibility patterns. A single regimen may not be optimal for 
management of newborn infections in different geographic regions since the etiology of 
infections and antimicrobial susceptibility patterns of major isolates may vary across settings. 
Moreover, antibiotic regimens that are not targeted for the leading young infant pathogens may 
contribute to treatment failures and emergence of multidrug-resistant bacteria in the community. 
Etiology of young infant infections in developing countries has been described in only a 
few studies, where 5-10% of cases of suspected serious infections were positive for any bacterial 
etiology by blood culture. 2,24,37-41 Etiology of more than 90% of suspected infection cases 
remains unknown.   The ANISA etiology study found very similar results, with 15.8% and 
12.2% of cases attributed to bacteria and viruses, respectively. 42  A proportion of these cases 
may be caused by bacteria or viruses that are currently unrecognized as causes of young infant 
infection. Additionally, most of these studies did not capture infants during the first 3 days of 
life, a period of high mortality. Notably, these studies did not collect specimens from healthy 
infants to act as a control group.  Finally, most studies were conducted in hospital settings; 
because of low care-seeking and inclusion of nosocomially-acquired infections, the pathogen 
distributions in these studies are unlikely to be representative of infections in the community.25 
Thus, despite the large burden of neonatal deaths in the community attributable to infections, 
there are almost no data on the etiology of community-acquired young infant infections, 2,3or 
geographic variation in etiology. 24,43 
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Clinical algorithms are useful to identify sick newborns with severe infection, particularly 
in settings where laboratories are not readily available. A 1999 community-based sepsis study 
conducted in rural India used the simultaneous presence of any two of seven signs: poor sucking, 
weak or no cry, limp limbs, vomiting or abdominal distension, cold to touch, retracting, 
umbilical infection.31 These indicators predicted presumed sepsis death in newborns less than 
one month of age with sensitivity of 100% and specificity of 92%. The criteria identified 10.6% 
of the neonates in the community with suspected cases of sepsis. 44 The Young Infants Clinical 
Signs Study Group in 2008 evaluated infants 0-6 days old and 7-59 days in outpatient health 
facilities and used the presence of any one of seven signs: history of difficulty feeding, history of 
convulsions, movement only when stimulated, respiratory rate of 60 breaths per minute or more, 
movement only when stimulate, severe chest in-drawing, temperature of 37.5°C or more or 
below 35.5°C. This study used these signs to predict an expert pediatrician panel’s clinical 
judgment of severe illness, requiring referral to a hospital for admission. The prediction model 
had a sensitivity of 85% and specificity of 75%.  10  
Recently, studies have validated community health workers’ (CHW) assessments of 
severe young infant disease using clinical algorithms comprised of similar signs as those that will 
were used in the ANISA study, compared to physician assessment as the gold standard. A 2009 
study documented CHW’s classification of very severe disease using a simple clinical algorithm 
with sensitivity of 73%, specificity of 98%, positive predictive value of 57% and negative 
predictive value of 99%.8 Similarly, another study the same year found CHW’s classification of 
very severe disease using a similar clinical algorithm to have a sensitivity of 91%, specificity of 
95%, PPV of 51% and NPV of 99%.  7 
8 
Evidence for revision of guidelines for treatment: trials of simplified antibiotic regimens for the 
treatment of infections in neonates  
In recent years, there has been a set of trials using standardized protocols to test the use of 
simplified antibiotic regimens that can be provided in low resource settings where referral to an 
inpatient facility or hospital may not be possible.  Three of the trials (SAT-Bangladesh, SAT-
Pakistan and AFRINEST-severe infections) studied whether young infants with clinical signs 
indicative of possible severe infection can be treated with a combination of oral amoxicillin plus 
gentamicin, and whether injections can be stopped after the first 2 days with a transition to oral 
amoxicillin alone for 5 days.  This could effectively reduce the number of injections given and 
making treatment regimens simpler to follow.  These equivalency trials examined whether 
adherence to regimens will differ between simpler antibiotic regimens when compared with the 
standard regimen of procaine penicillin and gentamicin injections daily for 7 days, using a 
predefined margin of +/- 5%. 
The results of the SAT-Pakistan trial per protocol analysis of 2780 infants showed that 
there was no significant reported risk difference in treatment failure within 7 days of enrollment 
between infants in the three treatment arms--the reference treatment (intramuscular procaine 
benzylpenicillin and gentamicin) when compared with the simplified treatment regimens of oral 
amoxicillin and gentamicin (risk difference: -1.9% (-5.1%, 1.3%) and procaine benzylpenicillin, 
gentamicin, and amoxicillin (risk difference: 1.1% (-2.3%, 4.5%).46 Similarly, the results of the 
SAT-Bangladesh trial also suggest that the same two simplified treatments were equivalent to the 
reference treatment of intramuscular procaine benzylpenicillin and gentamicin, with risk 
differences of -1.5% (-4.3%, 1.3%) and -1.7% (-4.5%, 1.1%), respectively.  47 
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The AFRINEST multisite equivalence trial was conducted in the Democratic Republic of 
Congo, Kenya, and Nigeria.  45 Neonates were visited by CHWs and assessed for any signs or 
symptoms of illness.  The infants were stratified by age of onset, and were randomized to one of 
four treatments:  intramuscular procaine benzylpenicillin-gentamicin for 7 days (reference); 
intramuscular gentamicin and oral amoxicillin for 7 days (risk difference: -1.9% (-4.4%, 0.1%); 
intramuscular procaine benzylpenicillin-gentamicin for 2 days followed by oral amoxicillin for 5 
days (risk difference: -0.6% (-3.1%, 2.0%); and intramuscular gentamicin for 2 days and oral 
amoxicillin for 7 days (risk difference: -2.7% (-5.1%, 0.3%)  All three simplified regimens were 
found to be as effective as the reference treatment of intramuscular procaine benzylpenicillin-
gentamicin for 7 days when administered on an outpatient basis.45 
Fast breathing as the only sign of illness among infants 0-59 days of age 
The AFRINEST trial also  studied equivalence of simplified antibiotic regimens in 
infants aged 0-59 days of age with fast breathing as their only sign, where their parents did not 
accept referral to a hospital48.  In this equivalency trial, 2196 infants were randomized in a per 
protocol analysis to either 1. Oral amoxicillin for 7 days or 2. A combination of intramuscular 
gentamicin plus procaine penicillin for 7 days.  The equivalency was defined as having a risk 
difference between +/- of 5%.  This study compared four different outcomes between the 
intervention group and the control group.  The first was treatment failure in the first week after 
enrollment in the study.  There was no significant difference between the 2 groups in this 
outcome, with a risk difference of -2.6% (-6.0%, 0.8%), although the lower limit of the 
confidence interval around the risk difference was lower than the equivalency margin. 49 The 
second was incidence of death by the 15th day after enrollment.  Again, the results showed 
equivalency between the two groups with an estimated pooled risk difference of -0.02% (-
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0.5%%, 0.5%).  The third was relapse of illness as defined by fast breathing as the only sign 
during the second week after enrollment.  As with the other outcomes, the two groups showed 
equivalency with a pooled risk difference of -0.02% (-1.2%, 1.6%).  Lastly, the fourth was 100% 
adherence to the scheduled doses of antibiotics on all 7 days or until the treatment failed.  
Adherence (defined as 100% of doses on all 7 days) was found to be better among the simplified 
regimen intervention group (98.5%) when compared with the reference regimen (90.7%). 49    
Figure 1. Revised algorithm for the management of sick young infants with possible serious 
infection, Guidelines for managing possible serious bacterial infection in young infants 
when referral is not feasible, World Health Organization, 2015. 50 
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These data provided some evidence for the recent revision of the guidelines for managing 
possible serious bacterial infection in young infants when referral is not possible.  The new 
guidelines further stratified infants meeting the possible serious bacterial infection (pSBI) case 
definition into a more severe (“critically ill”) and less severe (“clinical severe”) case definitions.  
The critically ill infants are now recommended aggressive antibiotic treatment in a hospital 
setting after receiving pre-referral antibiotic treatment, while the clinical severe cases are 
recommended simpler antibiotic regimens when referral to a hospital is not possible.  Lastly, the 
infants > 7 days with fast breathing as their only sign are recommended to receive oral antibiotic 
treatment with no hospital referral (Figure 1).   
Much of the evidence used to inform these guidelines was graded as low quality 
evidence, and a key data gap was comprehensive diagnostic evaluation of infants in the different 
case strata to allow for a link between infectious etiologies and clinical management 
recommendations.50  The important risk factors and modes of transmission for young infant 
infections also remain poorly understood.  51 Most studies have been conducted in developed 
countries, and has focused on early-onset neonatal sepsis and, even more specifically, group B 
Streptococcus (GBS).  
Evaluations of all-cause neonatal sepsis have commonly identified preterm delivery, low 
gestational age, intrapartum fever, chorioamnionitis, and prolonged ruptures of membrane as risk 
factors for early-onset sepsis. 52-54 The risk of early-onset neonatal sepsis also increases with 
number of vaginal exams during labor 53 54 An evaluation limited to early-onset invasive 
Escherichia coli infections identified low gestational age, prolonged rupture of membrane and 
intrapartum fever as the primary factors associated with increased risk. Risk factors for early-
onset GBS infections include maternal GBS colonization, intrapartum fever, preterm delivery, 
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prolonged rupture of membrane, having had a previous infant with GBS disease, and black race. 
55-57 Described factors associated with late-onset GBS sepsis are similar to early-onset sepsis, 
with preterm delivery as a stronger risk factor (50% of late onset cases compared to 25-30% of 
early onset cases). 58 However, environmental factors such as nosocomial transmission, person-
to-person transmission, and transmission via breast milk, may play an important role.  
One notable result of the ANISA etiology study was the high proportion attributable to 
Ureaplasma spp. infection. 42  Ureaplasma spp. are bacteria in the class Mollicutes, and are 
some of the smallest self-replicating microorganisms, with regard to cellular dimensions and 
genomic size. 59 Their small genomes result in part to the complex requirement for growth media 
in vitro, making them difficult to culture. 59  Ureaplasma infections are typically associated with 
adult disease, usually manifesting in upper urinary tract infections, or conditions complicating 
pregnancy, such as preterm labor, premature rupture of membranes, spontaneous term labor, and 
chorioamnionitis. 59-65 Ureaplasma has been identified in cerebral spinal fluid (CSF) of preterm 
infants presenting with hydrocephalus, sepsis, and meningitis. 65 In preterm infants, an 
association between Ureaplasma urealyticum and short and long term pulmonary morbidity, as 
well as mild cerebral impairment has also been described.66  Ureaplasma-associated neonatal 
infections primarily occur among preterm infants, and is not commonly reported as a pathogen 
causing neonatal illness in term infants, even in high income countries where data are more 
readily available.59,67   
Ureaplasma spp. were identified in higher numbers in infants with suspected infection 
compared to healthy infants.  Crude odds ratios (cORs) varied by specimen type and study site, 
ranging from 1.5 to 2.7. When stratified by age at onset of disease, cORs were higher for infants 
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with early onset disease.  cORs were 3.7 and 1.7 (p-value=<0.0001) for respiratory specimens 
and 1.4 and 1.3 for blood specimens among infants who died vs survived, respectively.   
The overall proportion of infants meeting the ANISA possible serious bacterial infection 
(pSBI) case definition with infections attributable to Ureaplasma spp. was 2.82% (1.93, 3.77%), 
the second highest proportion after respiratory synctitial virus (RSV), in a study where most of 
the pathogens were each responsible for <1% of infection.  There was not a significant difference 
in attribution between infants with early and late onset disease, but the proportion of attributable 
illness to Ureaplasma was higher among infants who died (8.3% (4.1, 12.3)) vs those who 
survived (2.7% (1.8,3.7)).  
While Ureaplasma spp. is recognized in the literature as a relevant infection for preterm 
neonates, the ANISA finding was unexpected.  While the ANISA cohort had 28% of sick infants 
with a gestational age of less than 37 weeks, only 2.9% of them were either extremely or very 
preterm (< 32 weeks of age).  Furthermore, the Ureaplasma finding was not limited to preterm 
infants. The cORs for Ureaplasma was higher in term infants than it was for preterm infants, at 
1.8 vs. 1.6 in respiratory specimens, and 1.5 and 1.3 for blood specimens, respectively.68   
A study using very similar methodology to ANISA conducted in infants in the first 3 
days of life in Soweto, South Africa also found Ureaplasma to be the leading etiology proportion 
(5.4%) among neonates under study. 69 
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CHAPTER 3: METHODS 
Parent Study Design and Population 
The Aetiology of Neonatal Infections in South Asia (ANISA) project, a multi-center, 
population based longitudinal study whose objective was to determine the population-based 
incidence, etiology and antibiotic resistance profiles of community-acquired young infant 
infections in Bangladesh, India and Pakistan, was conducted from 2010-2014 (Figure 2). This 
study followed women of child bearing age in defined catchment areas for pregnancy and birth 
outcomes.  Upon birth, each child was assessed for illness at 10 scheduled visits using the IMCI 
case definition for possible serious bacterial infection during the first 60 day of life.  Infants less 
than 60 days with at least one of the signs (history of convulsions, respiratory rate > 60/min, 
severe chest in drawing, axillary temp either >99.5 degrees F or <95.9 degrees F, little or no 
movement, and poor feeding) resulted in hospital referral and a regimen of either parenteral or 
oral antibiotics.  Infants with fast breathing as their only sign were not sampled routinely except 
in the Sylhet site.  In the analytic stage, an algorithm was used to ensure that an infant was 
considered a new case if the study physician confirmed that 1) the child met one of the above 
signs, 2) had not been hospitalized in the preceding 7 days (excepting post-natal hospital stays of 
facility-born infants), and 3) had not been previously enrolled as a case in prior 7 days. In the 
etiology study analysis, all cases who only had elevated respiratory rate were excluded.  
There were three major assumptions made when designing the parent study.  CHWs can 
assess the signs with sufficient precision to identify sick neonates most likely to have a 
laboratory confirmed invasive bacterial infection.  The ANISA case definition (IMCI criteria for 
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very severe disease) is sensitive enough to capture all cases of clinically important bacteremia.  
The laboratory methods are sensitive enough to detect a vast majority of bacteremias requiring 
antimicrobial therapy. 
Figure 2. Map of Aetiology of Neonatal Infections in South Asia (ANISA) Study sites,  
2011-14 
 
Source:  Dr. Samir Saha, Child Health Research Foundation 
A panel of neonatologists with expertise in neonatal infections was convened, and the 
Delphi method was used to identify a priority list of pathogens for testing of nasopharyngeal 
(NP) and oropharyngeal (OP) swabs and blood specimens from infants enrolled in the ANISA 
study70. 
Respiratory (nasopharyngeal and oropharyngeal swabs) and blood were taken from cases 
to test for presence of pathogens. A subset of healthy infants were visited and enrolled based on 
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age and date of children who met the case definition.  The same specimens were collected from 
healthy infants in order to provide a comparison group for baseline carriage of bacteria and 
viruses in the same population.  All blood specimens were tested using automated blood culture 
methods (for cases only) to detect bacteria, and by polymerase chain reaction (PCR) by TaqMan 
Array card (TAC) panel testing for 27 different bacteria and viruses, and respiratory specimens 
were tested by PCR TAC panel alone (Appendix 3). 71 Infectious disease specialists reviewed 
and classified each isolate as a pathogen or contaminant, based on clinical information on the 
patient, and other laboratory and antibiotic susceptibility data. The study surveillance and 
laboratory methods have previously been described.72-78 
Etiology was measured by estimating the probability that each organism class was 
attributed to a given case of illness.  These estimations were based upon the observed blood 
culture and molecular testing results, using a Bayesian partial latent class model method.  42,79 
These organism classes varied by study site, age of onset of illness, data of enrollment, and 
outcome (died with a specimen available within 7 days of death).  Pathogen lists created by a 
stepwise procedure that was informed by the number of across- class combinations of test results 
was used, and varied by study site.  False positive rates were estimated, and were allowed to vary 
across the aforementioned covariate levels, but the estimated true positive rates were held 
constant.  Posterior means were reported as the organism class proportions, with corresponding 
95% credible intervals (Appendix 4). 
Aim 1 Methods 
Case definitions  
  In accordance with WHO case definitions, we defined an infant with “clinical severe 
infection” as one who presented with at least one of the following signs: severe chest in-drawing, 
axillary temp either =>38°C or <35.5°C,  movement only when stimulated, and failure to feed 
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well (confirmed on observation by study personnel).11 We defined a “critically ill” infant as one 
who presented with at least one of the following signs:  lack of consciousness (no movement at 
all), inability to feed, inability to cry, physician-observed convulsions, apnea, cyanosis, bulging 
fontanelle, major congenital malformations inhibiting oral antibiotic intake, and persistent 
vomiting (defined as vomiting following three attempts to feed within 30 minutes). We defined 
an infant with late-onset isolated fast breathing as one aged 3-59 days with elevated respiratory 
rate (i.e. >=60/minute) as their only sign. We do not present the results for the early onset (< 3 
days of age) infants in this analysis.  Each of these case definitions are mutually exclusive.  All 
clinical signs used in these definitions were based on physician’s assessment. 
Data analysis 
  A partial latent class model was used to estimate pathogen population proportions for 
infants with clinical severe infection, and compare these proportions to those for infants who 
were critically ill and those with isolated late-onset fast breathing.  Statistical differences 
between proportions are defined as overlapping Bayesian 95% credible intervals. The 
comparison group for the critically ill infants consisted of all infants with clinical severe 
infection, while the reference group for the infants with late-onset isolated fast breathing was 
restricted to infants 3-59 days old with clinical severe infection.  Our analysis of infants with 
isolated fast breathing was limited to the Bangladesh site because this was the only site where 
respiratory and blood specimens were routinely collected from such infants. Our hypothesis was 
that critically ill infants would have a higher proportion of bacterial etiologies when compared to 
those with clinical severe infection, and that infants with isolated fast breathing in the late onset 
period (3–59 days) would have a lower proportions of bacterial etiologies when compared to 




 ANISA statistical methodology was an extension of the basic partially-Latent Class 
Model (pLCM) developed by Wu et al for the Pneumonia Etiology Research for Child Health 
(PERCH) to estimate the proportion of pneumonia infections attributed to one of six specific 
pathogens.80  We applied the same partial latent class Bayesian model as used in the primary 
study, which used a Gibbs sampler to estimate individual and population-level probabilities for 
each of 27 pathogens detectable on the molecular PCR TAC platform, and an “other/none” 
category, which included cases not attributed to any etiology.68,79 The Gibbs sampler is a Markov 
Chain Monte Carlo (MCMC) algorithm for obtaining a sequence of observations which 
approximate a specified multivariate probability distribution.  Each sequence was used to 
estimate the latent variables of etiology proportion and test characteristics, i.e. the true positive 
rate and false positive rate for every test and pathogen.  The detections in specimens obtained 
from healthy infants were used to set priors for the false positive rates in the model. We will use 
the same stepwise method for selection pathogen lists for incorporation to the model for every 
site.  A non-parametric Bayesian model will be used to adjust these estimates for covariates of 
age and time of enrollment.  Another class was indirectly calculated, i.e. not estimated by the 
model, for all other bacteria that were detectable by blood culture but did not have a 
corresponding molecular test. The mean, 2.5th and 97.5th percentiles for the Bayesian credible 
intervals are reported.  
We will hold the six main assumptions made in the primary etiology analysis, which are 
the following: 




• True positive rates will be held constant across site and other covariates (age and date of 
enrollment) because infection assumes presence of the pathogen in the clinical specimens 
collected from cases. 
• False positive rates will vary across site, age, and date of enrollment. 
• Enrolled healthy controls are not ill, and hence any detection of pathogens in clinical 
specimens is considered carriage. 
• We assume conditional independence, in that the carriage of one pathogen will not affect 
carriage of another pathogen, if neither of them are the cause of the illness. 
• We will set lower limits for TAC test true positive rates: 40% for respiratory molecular 
tests and 20% for Blood molecular tests.  We did not set a lower limit for blood culture 
true positive rates.  Blood culture results are held as a gold standard, with the assumption 
that the true positive rate is 100% and the false positive rate is 0%. 
Model specifications 
The probability of observing {𝑦𝑖𝑘} is expressed by a linear mixture model with {𝜋𝑘} as 
the mixing coefficients.  By applying the regular conditional independence assumption for  linear 
mixture class models with unknown latent classes, and a further assumption that the probability 
of test  𝑇𝑘 to produce positive test result depends only on whether pathogen 𝑘 is the true etiology 
of the tested case, Wu et al. developed a partially-Latent Class Model (pLCM) 80: 
 


















Here parameters  𝜃𝑘 = 𝑓(𝑦𝑖𝑘 = 1 | 𝑡𝑟𝑢𝑒 𝑒𝑡𝑖𝑜𝑙𝑜𝑔𝑦 = 𝑘) and 𝛿𝑘 = 𝑓(𝑦𝑖𝑘 = 1 | 𝑡𝑟𝑢𝑒 𝑒𝑡𝑖𝑜𝑙𝑜𝑔𝑦 ≠
𝑘) are called the True Positive Rate (TPR) and False Positive Rate (FPR) respectively for 




Rationale for using partial latent class analysis model 
Determining etiology of neonatal infections, particularly in low resource settings, is 
complex.  Previously, other studies in the literature have conducted descriptive analyses of blood 
culture results only in an effort to characterize the etiology of neonatal infections.2  In more 
recent years, studies such as the Global Enteric Multicenter Study used an attributable etiologic 
fraction approach.  Both of these approaches have a number of limitations.  The methods makes 
implicit assumptions about perfect sensitivity of all laboratory tests, there is no way to combine 
results for the same pathogen across multiple specimens, there is no way to get an etiologic 
attribution at the individual level, and there is not a straightforward way to adjust for covariates. 
82 In the case of the ANISA study, we had varying number of tests (between 1 and 3) for each of 
the 27 pathogens selected for the molecular panels, and two different types of specimens (blood 
and NP/OP swabs).   In an ideal world, we would identify infants with serious infections using a 
case definition with high sensitivity and specificity, we would obtain ideal samples and test them 
using laboratory tests with high sensitivity and specificity.  In reality, the laboratory tests used 
have imperfect test characteristics.  While blood culture, which is a historical “gold standard” 
and is typically assumed to have 100% sensitivity, it has unknown specificity -- we have no 
blood culture results from controls to inform specificity.  The molecular platform used has been 
analytically but not clinically validated, 83 so we do not know the test characteristics of these 
tests.  This method was chosen for its ability to incorporate multiple tests per pathogen for a 
given case into the estimation of pathogen probabilities at an individual and population level, and 
allowed us to quantify the uncertainty around diagnostic tests. 42,79,84This decision was informed 
by another multicenter study estimating the etiology of pneumonia in children under 5 years of 
age.  They developed a partially latent class model which was adapted for the ANISA etiology 
study. 80,81,84,85 The ANISA primary etiology study has made a number of innovations to this 
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method, including building in a non-parametric conditional density estimation to control for 
confounding, and establishing a method for pathogen selection into the model based on the 
number of novel combinations identified between detections and covariates. 
Infants with at least one clinical specimen available were included in the analysis. For the 
analysis including infants with isolated fast breathing, we used the same true positive rates as 
estimated by the ANISA etiology model (we set these values as constants, and therefore they 
were not estimated by the model). The Bayesian partial Latent Class Analysis will be conducted 
using R! and R! Studio and the clinical signs analysis will be conducted using SAS software 
version 9.3®. 86,87 
Distribution of clinical signs among cases with infectious etiology 
  To examine the distribution of clinical signs among infants who met the clinical severe 
infection case definition and had an infectious etiology, we used the clinical severe infection 
model output, which generates an estimated probability for every pathogen. We calculated the 
posterior probability for every sign in the IMCI case definition using the standard Bayesian 
formula: P(clinical sign|infectious etiology)=P(clinical sign x infectious etiology)/P(clinical 
sign).88 We then used the posterior probabilities from every iteration to obtain a distribution for 
each sign, and reported the median as the point estimate and 2.5th and 97.5th percentiles for the 
Bayesian credible intervals. We stratified these probabilities by early and late onset of disease. 
Within these categories, we further stratified by attribution to a bacterial versus viral etiology.  
Study power 
We are using a cohort from the parent ANISA study, in which 5,253 cases and 1,865 
healthy controls were enrolled; hence, our sample size is fixed.   There are no known methods 
that allow to estimate power for a Bayesian partial latent class model. In order to estimate power 
for this analysis, we estimated what our power would be if we used the population attributable 
  
22 
fraction method.89  We will use the estimated power as a proxy for power using the pLCM 
method, with the knowledge that EF method does not taking into account confounding, which 
decreases power.  We ran a simulation of different sized cohorts between 1000-6000 enrolled 
cases, varying our assumptions on the true etiology rate for one hypothetical pathogen between 2 
and 6%.  We assumed the true etiology proportion would be +/- 2% of the estimated etiology 
proportion.  We held the true positive rate constant at 80% and the false positive rate constant at 
10%.  Our etiology fraction formula calculated under these simulated conditions is the following: 
̂p= (pobs – FPR) / (TPR - FPR).90 
Our cohort is slightly less than 5000 subjects:  the estimated power for a true etiology rate 
of 2% given a cohort of 5000 is 94% (Figure 3).  Note that the higher the true etiology rate, and 
the larger the cohort, power increases.  Even at the lower true etiology proportions and smaller 
cohort sizes, the smallest estimated power is 64%. 
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Figure 3. Estimated power curves using the etiologic fraction method under different 
underlying assumptions about sample size, true etiology proportion, true positive rate, and 
false positive rate for one hypothetical pathogen 
 
Study limitations 
This analysis has a number of limitations.  We are limited to the universe of those infants 
who met the case definition. Ideally, we would run a predictive model to measure which clinical 
signs best predict the outcome of each infectious etiology; however, we cannot use this method 
because the outcome itself is defined by the clinical signs.  Similar to the main ANISA etiology 
study, we will set no bounds on the true positive rate for the blood culture sensitivity.  That 
coupled with a much smaller sample size, we believe that the estimated proportion for certain 
pathogens, such as Salmonella, with a low true positive rate but a good number of detections, 
may be inflated.  There are other criteria included in the critically ill case definition that were not 
































Size of Simulated Cohort
2% 4% 6%True etiology proportion
  
24 
requiring transfusion, surgical conditions needing hospital referral, and fast breathing day 0-6 
(this criterion was evaluated separately in Sylhet only). 
Missing data 
There was a low proportion of cases with missing data (<5%), and we assumed that these 
data were missing at random. Although considerable effort was made to reach infants on day 0 of 
their lives, there were many severely ill infants that went on to die who were missed on the first 
hours of life.  Hence, the parent study was only able to collect clinical specimens on 9% of all 
deaths. 
Aim 2 Methods 
Preliminary data 
We were originally concerned there could be a difference in colonization with 
Ureaplasma spp. based on whether an infant is delivered term or preterm, i.e. if the observed 
association between presence of Ureaplasma bacteria and meeting the case definition might have 
been driven by over representation of preterm infants among the cases versus controls.  We 
modeled Ureaplasma detections as a function of study site, age, and gestational age, with 
inclusion of an interaction term between gestational age and whether an infant was a case or 
healthy infant.  The data from the linear regression model showed that the detections uniformly 
decrease as gestational age increases in both groups, and the interaction term was not significant.  
Therefore, the Ureaplasma proportion found in the cases is likely not driven by preterm infants 




Figure 4. Distribution of gestational age among both cases and controls with detections of 
Ureaplasma spp. in their blood and respiratory specimens, Aetiology of Neonatal Infections 
in South Asia (ANISA) Study, 2011-14 
 
+ healthy infants  ° cases 
The assay used to detect Ureaplasma spp. was analytically validated for serotypes 1, 3, 6, 
and 14 for U. parvum and serotypes 2, 4-5, and 7-13 for U. urealyticum. 71 Specificity of each set 
of primers was evaluated using the Basic Local Alignment Search Tool (BLAST) National 
Center for Biotechnology Information (NCBI) database. An internal no-template control and a 
positive control were incorporated into the TAC design, to detect card or individual assay or 
extraction failures.  In the event of a card failure, the card was re-run until the controls indicated 
valid results.  Extraction failures resulted in re-extraction and testing for that specimen.  All 
specimens in which Ureaplasma spp. were detected went on to speciation to U. parvum or U. 
urealyticum using real-time PCR. 68    
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Etiologic attribution methods 
We used the etiology results from the ANISA Bayesian model (pLCM) using a Gibbs 
sampler to estimate individual and population-level probabilities for each pathogen on the 
molecular PCR TAC platform, and an “other/none” category, which included cases not attributed 
to any etiology. 68,79-81,84  
The ANISA etiology attribution model was evaluated by simulation studies. 79 These 
studies identified scenarios, or “danger zones” in which the model does not perform well, e.g. the 
model will not converge, or estimates are more vulnerable to bias and inaccuracy.  For the 
ANISA pLCM model, these scenarios included: when pathogens have only one laboratory test 
result available (i.e. only one molecular test); if the true pathogen population proportion is very 
low (<0.5%); if the crude odds ratio is less than 1; if the false positive rate is high (greater than 
75%), or if the true positive rate and false positive rate for that pathogen are close together (less 
than 25% difference between the two). 79  
Key terms and definitions 
 A high grade fever of a pregnant woman was defined as a self-reported temperature 
>38.0`C (>100.4`F). Any complications during pregnancy was defined as having one of the 
following: high grade fever, foul smelling discharge, swelling of face or feet, excessive bleeding, 
or convulsions. A skilled provider or skilled birth attendant was defined as a licensed, qualified 
doctor, nurse, midwife, or paramedic. Maternal poor nutritional status was defined as mid upper 
arm circumference of less than 21.5 centimeters. Received full antenatal package was defined as: 
1. receipt of at least 2 antenatal visits from a community health worker; and 2. Receipt of 2 
tetanus toxoid injections during current pregnancy, or 1 tetanus toxoid injection and at least 4 
shots pre-pregnancy, or at least 5 tetanus toxoid injections pre-pregnancy; and 3. Receipt of at 
least one iron tablet or dose or iron syrup during current pregnancy.  Delivery at a health facility 
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was defined as being born at a public or private hospital, a maternity center, or clinic. Any other 
complication during labor/delivery was defined as excessive bleeding, convulsions, retained 
placenta, abnormal presentation, prolonged labor, or premature water breaking.  
Proper tying and cutting of umbilical cord was defined as use of an acceptable device for 
both cutting and tying the umbilical cord.  Acceptable devices for cutting cords in the home must 
have been boiled and be either thread, clip kit, knife, blade, or tongs.  Acceptable devices for 
cutting cords in a hospital or health facility must have been nurse/doctor’s scissor or clip kit.  
Acceptable devices for tying cord in the home must have been boiled and be either a clip, clip 
kit, thin rope brought by doctor, blade, or rubber band.  Acceptable devices for tying a cord in a 
hospital or health facility were a clip or clip kit.   Proper application of antibiotic or antiseptic to 
the umbilical cord differed by setting.  In the home, antibiotic or antiseptic must have 
beenapplied to the stump.  In the hospital, antibiotic or antiseptic can be applied, or nothing can 
be applied.  Delayed breath or crying was defined as a delay of either breathing or crying greater 
than 1 minute after delivery. 
A case was defined as a registered infant between 0 and 59 days of age that presented 
with one of the following signs, as confirmed by a physician:  respiratory rate >=60/minute (fast 
breathing), severe chest in-drawing, axillary temperature either =>38°C (fever) or <35.5°C 
(hypothermia), movement only when stimulated or no movement at all, convulsions, or not 
feeding well confirmed on observation by study personnel.  A healthy infant was an infant who 
did not meet the case definition at the time of clinical specimen collection.  Early onset disease 
was defined as illness occurring less than 3 days of age; late onset disease was defined as illness 
occurring between 3 and 59 days of age.  Preterm was defined as an infant with gestational age 
of less than 37 weeks. Low birth weight is defined as an infant weighing <2500 g at birth. 
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A positive detection in a case was defined by a positive result on a TAC card from either 
respiratory or blood specimens.   An average individual probability was the likelihood estimated 
by the ANISA pLCM model that a given organism was the causative agent of illness for a given 
case.  The Ureaplasma attributable population is the aggregated proportion of individual 
probabilities across site and weighted by number of cases enrolled per month in that site.  
Ureaplasma attributable cases were defined as individual infants who met the ANISA case 
definition, with a probabilistic assignment of Ureaplasma as the causative agent of illness, based 
on the estimated pLCM model results.  The true positive rate (TPR) is defined as the probability 
of having a positive test if the case is caused the pathogen.  The false positive rate (FPR) for a 
pathogen is defined as the probability of having a positive test result for a subject that does not 
have the pathogen as the etiologic cause of illness.  
Concordance between respiratory and blood tests was calculated using the number of 
infants with detections in both blood and respiratory specimens, divided by the total number of 
detections in either specimen type.   
To examine whether Ureaplasma could be construed as a commensal organism co-
occurring with other organisms that were the true cause of infection, we compared the observed 
distribution of pathogen detections between healthy infants and infants with Ureaplasma illness. 
In order to obtain a population of infants with Ureaplasma attributable illness, we randomly 
sampled the Ureaplasma individual probabilities generated from the ANISA pLCM model.  
Random sampling of this output probabilistically assigned a binary value (yes, no) for 
Ureaplasma as the causative agent of illness, 28,29 and we sampled the population 50 times to 
quantify variability in the estimates.  We calculated a mean value with 95% credible intervals for 
the number of detections across all 50 samples. We then compared the proportion of organisms 
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detected in healthy infants with the proportion of mean detections in infants with Ureaplasma 
illness.  Proportions were compared using the Z statistic, at alpha level=0.05.  
To evaluate whether Ureaplasma illness could instead be attributed to other pathogen(s), 
we analyzed the subset of infants with an individual Ureaplasma probability >50%, i.e. a subset 
with a high probability of illness attributable to Ureaplasma.  We compared the average 
individual probabilities for all organisms for this subset both with and without the Ureaplasma 
contribution to etiology included by removing the Ureaplasma probabilities and rescaling the 
remaining pathogen attribution probabilities to sum to 100%. 
To describe the deaths among infants with Ureaplasma-attributable illness in this 
population, we compared the average individual Ureaplasma probabilities among cases who died 
and who survived, to ascertain if there was a higher median probability of Ureaplasma 
attribution among deaths. 
To describe characteristics among Ureaplasma attributable population, 30 we calculated 
the posterior probability for each selected variable, based on the ANISA pLCM output, using the 
standard Bayesian formula: P(variable|Ureaplasma etiology)=P(variable x Ureaplasma 
etiology)/P(variable). We then used the posterior probabilities from every iteration to obtain a 
distribution for each variable; point estimates (means) and 95% Bayesian credible intervals 
(2.5th and 97.5th percentiles) were reported. We stratified these probabilities by early and late 
onset of disease, and separately by preterm and full-term gestational age.  Credible intervals 
based on an alpha=0.05 that did not overlap were considered statistically significant. 
Study power 
We performed a power calculation for a case control analysis using logistic regression.  
Assuming a 5% alpha level, with ~240 cases and ~57,000 controls, and an average exposure 
proportion in the controls of 25%, we estimate our power to be 80% to detect an odds ratio of at 
  
30 
least as high as 1.5.  If we varied the exposure proportions to 15%, 20%, and 40%, the 
corresponding power to detect an odds ratio of at least 1.5 is 70%, 77%, and 86%, respectively. 
Study limitations 
There are a high number of infants meeting the case definition from the etiology study 
that had a low probability (<10%) of their illness attributable to Ureaplasma spp.  The results of 
the second analysis may have been strengthened if we had observed a larger number of infants 
with a higher probability of Ureaplasma spp. infection among our case population, allowing us 
to limit our analysis to these infants. Data collection was nearly 100% complete for all cases, but 
the level of missingness is higher among the larger cohort.  The assessment of missingness is not 
complete for all variables of interest, we do know that the number of antenatal care visits (28%), 
first birth (13%), and materials used to cut and tie the umbilical cord (12%) have over 10% 
missing values.  
Risks to Human Subjects 
Human subjects involvement, characteristics and design 
IRB approval for the ANISA study was obtained from each of the study sites’ local IRBs 
in Bangladesh (International Centre for Diarrhoeal Disease Research, Bangladesh), India (Asian 
Institute of Public Health and Christian Medical College), and Pakistan (Aga Khan University), 
as well as partner institutions of Johns Hopkins University Bloomberg School of Public Health 
and the Hospital for SickKids.  The Centers for Disease Control and Prevention relied on all 
local IRBs for ethical review.  Consent was obtained from all mothers or caregivers who were 
enrolled in this study.  
The study is a secondary analysis of the ANISA cohort.  We used data previously 
collected on 63,114 infants and enrolled in the pregnancy and infant surveillance, which includes 
5,253 infants that met the case definition, and 1895 healthy controls.  Both study objectives are 
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included under the original written consent form obtained from the mother/caregiver at study 
enrollment.  The study population will include mothers and their infants originally enrolled in the 
parent study.  No new enrollment occurred study.   Young infants are included as the study 
results will be directly beneficial for them and consent will be obtained from their parents/care 
givers.   
Patient confidentiality   
All the research documents and specimens are held confidential and only shared with 
individuals who are directly involved in the study. Study questionnaire and data forms are kept in 
a secured place and accessible only to study staff. The patient identifiers were separated from the 
coded questionnaires and kept in locked file at study sites.  No personal identifiers were entered 
in the database, and no personally identifiable information was ever shared with CDC staff. Data 
confidentiality will be maintained at all times. No personal identifiers will be used in any reports 
or publications of study. 
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CHAPTER 4: INFECTIOUS ETIOLOGIES OF NEONATAL ILLNESS CLASSIFIED 
USING WORLD HEALTH ORGANIZATION DEFINITIONS 
Results 
There were 934 infants in the critically ill category, 3769 in the clinical severe infection 
category, and 738 in the late onset isolated fast breathing category.  Infants meeting the critically 
ill case definition and the clinical severe infection case definition were more likely to have been 
born preterm or low birth weight when compared to late onset isolated fast breathing infants 
(Table 1). Critically ill infants were significantly more likely to be hospitalized (48.8%) or died 
within 7 days of illness onset (18.2%) when compared with those who met the clinical severe 
infection case definition (31.8% hospitalized, 3.7% died) and those with isolated fast breathing 
(14.5% hospitalized, 1.6% died).  ANISA only captured clinical and diagnostic data on 9% of 
infants who died within 3 days of illness onset.18  Among the 9% of deaths for which a physician 
assessment was performed, respiratory and blood specimens were collected from 9.5% of infants 
in the clinical severe infection group, 22.9% of those in the critically ill group, and 2.1% of those 
in the isolated fast breathing group.  
Among those infants meeting the case definition for clinical severe infection, the leading 
pathogens identified were respiratory syncytial virus (RSV) (6.9%; 95%CI: 6.2%, 7.9%), 
Ureaplasma spp. (3.1%; 95%CI: 2.1%, 4.1%), and other bacterial pathogens not tested for by 
TAC (2.4%; 95%CI: 2.0%, 3.0%). A large proportion of the population with clinical severe 
infection (71.7%; 68.9, 74.5) did not have an etiologic attribution (Figure 5).  
A comparison of episodes attributable to pathogens in the critically ill group versus the 
clinical severe infection revealed more illness attributable to bacteria in the critically ill (33%) 
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vs. clinical severe infection group (14%). Higher proportions of critically ill infants were 
attributed to other bacterial pathogens not tested for by TAC (7.9%; 95%CI: 6.2%, 9.8%), 
Klebsiella pneumoniae (5.6%; 95%CI: 3.2%, 8.3%), E. coli (3.9%; 95%CI: 2.5%, 5.8%) and 
Ureaplasma spp. (5.5%; 95%CI: 3.6%, 7.7%). (Figure 2). A higher proportion of critically ill 
case episodes were attributed to any infectious etiology (41.8%; 95%CI: 36.3%, 48.2%) 
compared to clinical severe infection case episodes (27.1%; 95%CI: 24.3%, 30.4%). 
Overall, 9% of late onset isolated fast breathing cases had an attributable bacterial 
etiology (Figure 6). RSV was the leading pathogen among infants with late onset isolated fast 
breathing (3.4%; 95%CI: 2.0%, 4.9%) and those with clinical severe infection (15.7%; 95%CI: 
13.0%, 18.1%); however, the proportion of episodes attributable to RSV was much higher 
among infants with late-onset clinical severe infection.  There were significantly higher 
proportions of E. coli (1.4% (95%CI: 0.6%, 2.7%) vs 0.1% (95%CI: 0.1%, 0.5%)) and 
Enterovirus/Rhinovirus (4.2% (95%CI: 2.4%, 6.5%) vs 0.8% (95%CI: 0.1%, 1.8%)) in the 
clinical severe infection group when compared with the late onset isolated fast breathing group.  
Although not significant, almost all of the pathogens had higher proportions in the clinical severe 
infection group, except for Salmonella and human metapneumovirus.  A significantly higher 
proportion (82.5%; 95%CI: 78.7%, 86.0%) of the isolated fast breathing cases could not be 
attributed to any etiology, as compared with 51.3% (95%CI: 45.7, 59.9) of late-onset clinical 
severe infection cases.  
A comparison of the clinical presentation of infants with clinical severe infection among 
those with a bacterial vs. viral etiology showed several significant differences in proportions of 
danger signs between the two groups (Table 2a). Those with bacterial etiology had significantly 
higher proportions of hypothermia (12.2% (95%CI: 10.9%, 13.4%) vs 3.7% (95%CI: 2.9%, 
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4.4%)), movement only when stimulated (18.6% (95%CI: 17.0%, 20.1%) vs 6.5% (95%CI: 
5.5%, 7.6%)), convulsions (4.5% (95%CI: 4.0%, 5.1%) vs 1.5% (95%CI: 1.2%, 1.9%)), and poor 
feeding (47.9% (95%CI: 45.1%, 50.5%) vs 26.1% (95%CI: 24.3%, 28.0%)) when compared to 
those with a viral etiology. Infants with viral attribution had higher proportions of fast breathing 
(42.4% (95%CI: 41.2%, 43.6%) vs 37.3% (95%CI: 35.7%, 38.3%)) and severe chest in-drawing 
(51.1% (95%CI: 48.6%, 53.6%) vs 22.0% (95%CI: 19.8%, 24.3%)) when compared to those 
with a bacterial etiology.  When further stratifying this comparison by early and late onset of 
illness, there were significant differences in clinical presentation between those infants with early 
and late onset of disease (Table 2b).  Among infants with early onset of disease, there was a 
significantly higher proportion of infants with movement only when stimulated or no movement 
(24.2% (95%CI: 21.8%, 26.6%) vs 12.0% (95%ci: 6.2%, 18.2%)) and poor feeding (67.3% 
(95%CI: 63.8%, 70.2%) vs 54.7% (95%CI: 45.6%, 62.3%)) in the bacterial etiology group when 
compared to the viral group.  Among infants with late onset disease, the bacterial etiology group 
had significantly higher proportions of every sign except for fast breathing and severe chest in 
drawing, which were higher in the viral etiology group.   When comparing the bacterial etiology 
groups across early and late onset of disease, there were significantly higher proportions of every 
sign in the early onset group, except for severe chest in drawing and fever, which were 
significantly higher in the late onset group. When making the same comparison in the viral 
etiology group, there were significantly higher proportion of infants with hypothermia, 
convulsions, and poor feeding in the early onset group, while there were higher proportions of 
infants with severe chest in drawing in the late onset group.    
Discussion 
Limited etiologic evidence was available to inform the development of the original IMCI 
guidelines for management of illness in young infants; in particular, the studies available were 
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limited by small sample sizes and blood culture as the only diagnostic test.26-28  The ANISA 
study is the first of its kind to characterize the etiologic spectrum in young infants presenting 
with pSBI in a large prospective multisite cohort study in settings where referral refusal is high. 
Infants meeting the critically ill case definition had higher proportions of bacterial infections 
(33%), which warrants continued reinforcement that referral is imperative for infants in this 
category. 
The data for young infants with late onset isolated fast breathing generally support the 
revised guideline that recommends treatment of infants in this category with outpatient oral 
antibiotics. While 18% of pSBI cases in this group were attributed to any infectious etiology, 
half of these were attributed to viral infection.  
Most notably, while the etiologic data support recent WHO distinctions in clinical 
presentation, there is still a large proportion of unexplained illness in all three groups of infants, 
despite testing for 28 pathogen classes. While it is possible that specimens obtained in ANISA 
were not adequate to detect all infections (e.g., no collection of cerebrospinal fluid or urine), or a 
pathogen contributing to the unexplained etiology group was not included in the test panel (i.e. 
the diagnostic methods used were not able to identify all potential etiologies), it is also plausible 
that many episodes of pSBI are not caused by acute infection.  
Given that the majority of young infants in the ANISA cohort had an unexplained illness 
etiology, we further examined the clinical presentation of infants meeting the clinical severe 
infection definition in an effort to identify clinical signs associated with bacterial as opposed to 
viral infections. Infants in the clinical severe infection group with a bacterial etiology had 
significantly higher proportions of the clinical signs typically associated with more severe 
infection (such as hypothermia, convulsions and movement only with stimulation).  Although 
  
36 
there were some individual clinical signs that were more prevalent among infants with bacterial 
versus viral etiologies or vice versa, there is no evidence that individual signs or groups of signs 
can be used to predict bacterial versus viral etiology. While recent research suggests that 
biomarkers such as C-reactive protein and certain toll-like receptors29, as well as new meta-
genomic sequencing to rapidly identify pathogens from normally sterile fluids, may help 
diagnose infection, it is unlikely that physicians would have this information or technology 
available in low resource public health settings.   In light of these data, these data do not provide 
supportive evidence for further refinements to the case definition to distinguish bacterial from 
viral infection based on clinical signs. 
While the proportion of infants with a bacterial etiology was highest in the most severe 
category, and lowest in the least severe category, there was still a non-zero proportion of those 
with bacterial etiology in every category.   If the trials conducted in Africa and South Asia that 
evaluated the equivalency of simpler antibiotic regimens to the conventional regimens 14-16 had 
limited their study population to those with a bacterial etiology, simplified regimens may not 
have performed as well.  However, in the absence of a method available to identify etiology of 
illness more readily in low resource settings, this analysis supports the current set of case 
definitions and the 2015 WHO guideline as appropriate tools for referral and treatment among 
those refusing referral. 
Lastly, although currently recommended treatment regimens target most of the bacteria 
identified in infants in all three illness categories defined by WHO; Ureaplasma represents a 
comparatively high proportion of infection in all groups.  Ureaplasma has not been identified 
previously as a relevant pathogen for this age group, and the currently recommended regimens 
(typically gentamicin or amoxicillin) would not be effective against this agent. Regimens used to 
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treat Ureaplasma infection typically include macrolides or tetracyclines. 30 In the most severely 
ill infants in the ANISA population, 5.5% of episodes would not have received antibiotic therapy 
effective against the etiologic agent of illness. 
  While some analyses presented here have a small sample size, such as the comparison of 
etiologic proportions among infants with late onset isolated fast breathing vs. infants with 
clinical severe infection, these are the first data that describe the etiology of infections in young 
infants meeting all three WHO case definitions.  Ascribing etiologic attribution is challenging, 
due to the fact that every infant has multiple results for many pathogens.  While the pLCM 
method allows for use of multiple test results to be used in the estimation of etiology proportions, 
there are certain circumstances and conditions when using the pLCM methods, such as low 
number of positive detections, or having only a single test available for a given pathogen, where 
estimation of the true etiology proportion has limited reliability.  These are important aspects of 
our study to consider when interpreting the results. A series of simulations to validate this model 
identified mitigation strategies for the scenarios in which we have single tests available or low 
number of positive detections, such as inclusion of pathogens which have multiple tests and high 
number of detections, and subjecting pathogens with a single test or low numbers of detections to 
a rigorous selection process.23  As in the parent study, we incorporated these strategies, hence we 
believe the model results were reliable for our analysis.    
The ANISA study was conducted in countries with relatively high burden of neonatal 
disease and mortality, and high rates of refusal of referral for treatment/hospitalization, thereby 
providing the appropriate population to describe vital data on the etiologic spectrum of disease in 
young infants.  The data suggest it would be difficult to develop a clinical algorithm to 
distinguish bacterial from viral infections. Furthermore, none of the case definitions evaluated 
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here   distinguish well between infectious and non-infectious causes of illness. While infants are 
likely being unnecessarily treated with antibiotics in these settings, given they meet the case 
definition but may have a viral etiology or no infectious etiology at all, there are infectious 
etiologies found even among the least severely ill infants. These data suggest that there may be a 





Table 1. Characteristics of infants presenting with possible serious bacterial infection 11, 
stratified by World Health Organization case definition, Aetiology of Neonatal Infections in 
South Asia (ANISA) Study, 2011-14 











Characteristic (% unless otherwise specified)    
Infant 934 3769 738 
   Male 545 (58.3) 2114 (56.1) 441 (59.8) 
   Preterm 268 (28.7) 1050 (27.9) 132 (17.9) 
   Low birthweight 357 (38.2) 1373 (36.4) 185 (25.1) 
pSBI episodes 992 4000 771 
   Early-onset1 508 (51.2) 2448 (61.2) 0 
Integrated Management of Childhood Infection 
Signs 
   
      Respiratory rate >=60 breaths per minute 375 (37.8) 1580 (39.5) 771 (100) 
     Severe chest in-drawing 153 (15.4) 1086 (27.2) 0 
     Axillary temperature =>38.0`C (>100.4`F) 229 (23.1) 1608 (40.2) 0 
     Axillary temperature <35.5`C (<95.9`F) 157 (15.8) 377 (9.4) 0 
     Movement only when stimulated 307 (31.0) 332 (8.3) 0 
     No movement at all (unconscious) 44 (4.4) 0 0 
     Convulsions (confirmed by observation) 223 (22.5) 0 0 
     Poor feeding (confirmed by observation) 680 (68.6) 1455 (36.4) 0 
Other Signs    
      Bulging fontanelle 40 (4.0) 0 0 
      Persistent vomiting 64 (6.5) 0 0 
      Unable to cry 306 (30.9) 0 0 
      Presence of apnea 92 (9.3) 0 0 
      Presence of cyanosis 314 (31.7) 0 0 
   Child Hospitalized 484 (48.8) 1562 (31.8) 112 (14.5) 
   Child Died2 227 (22.9) 251 (9.5) 16 (2.1) 
   Child Died within 7 days of episode2 181 (18.2) 146 (3.7) 12 (1.6) 
1 Early onset is defined as < 3 days of life 




Table 2. Distribution of signs among infants meeting the clinical severe infection case 
definition (n=4000), by viral or bacterial etiology, Aetiology of Neonatal Infections in South 
Asia (ANISA) Study, 2011-14 






% (95%CI)  
Characteristic (% unless otherwise specified)   
      Respiratory rate >=60 breaths per minute 37.3 (35.7,38.8) 42.4 (41.2, 43.6) 
     Severe chest in-drawing 22.0 (19.8,24.3) 51.1 (48.6, 53.6) 
     Axillary temperature >38.0`C (>100.4`F) 32.9 (31.2, 34.9) 32.8 (31.1, 34.4) 
     Axillary temperature <35.5`C (<95.9`F) 12.2 (10.9, 13.4) 3.7 (2.9, 4.4) 
     Movement only when stimulated or no  
     movement 
18.6 (17.0, 20.1) 6.5 (5.5, 7.6) 
     Convulsions (confirmed by observation) 4.5 (4.0,5.1) 1.5 (1.2, 1.9) 
     Poor feeding (confirmed by observation) 47.9 (45.1, 50.5) 26.1 (24.3, 28,0) 
1 Early onset is defined as < 3 days of life  
2 Late onset is defined as => 3 days and <60 days of life 
3 Temperature was obtained in F, but reported in C after conversion 
 
Table 3. Distribution of signs among infants meeting the clinical severe infection case 
definition (n=4000), by age of onset and bacterial and viral etiology, Aetiology of Neonatal 
Infections in South Asia (ANISA) Study, 2011-14 




Late onset2  
% (95%CI) 
Characteristic (% unless otherwise specified)   
 Bacterial Viral Bacterial Viral 
      Respiratory rate >=60 breaths per minute 41.8 (39.7, 43.8) 38.4 (32.2, 44.4) 34.5 (32.6, 36.5) 42.7 (41.4, 44.0) 
     Severe chest in-drawing 9.6 (8.5, 10.7) 5.7 (3.1, 9.7) 29.6 (26.7, 32.6) 54.2 (51.9, 56.3) 
     Axillary temperature >38.0`C (>100.4`F) 26.1 (23.3, 29.4) 29.5 (21.0, 40.5) 37.1 (35.2, 38.9) 33.0 (31.5, 34.5) 
     Axillary temperature <35.5`C (<95.9`F) 19.8 (17.8, 21.8) 24.0 (17.7, 30.2) 7.5 (6.4, 8.5) 2.3 (1.9, 2.7) 
     Movement only when stimulated or no  
     movement 
24.2 (21.8, 26.6) 12.0 (6.2, 18.2) 15.2 (13.7, 16.7) 6.1 (5.2, 7.1) 
     Convulsions (confirmed by observation) 8.4 (7.3, 9.5) 5.6 (2.3, 9.2) 2.1 (1.8, 2.5) 1.2 (1.0, 1.4) 
     Poor feeding (confirmed by observation) 67.3 (63.8, 70.2) 54.7 (45.6, 62.3) 36.0 (33.2, 38.9) 24.2 (22.4, 25.9) 
1 Early onset is defined as < 3 days of life  
2 Late onset is defined as => 3 days and <60 days of life 




Figure 5. Estimates from a partial latent class model of the prevalence of pathogens in 
infants meeting clinical severe infection case definition (N=4000), Aetiology of Neonatal 




Figure 6. Estimates from a partial latent class model of the prevalence of pathogens in 
infants meeting the critically ill case definition (n=992) compared to those meeting the 






Figure 7. Estimates from a partial latent class model of the prevalence of pathogens in 
infants presenting with isolated fast breathing (n=771), compared to those meeting the 
clinical severe infection case definition (n=1552), late onset of illness (=>3 - 59 day 
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CHAPTER 5: CHARACTERIZING NEONATES WITH ILLNESS ATTRIBUTABLE TO 
UREAPLASMA SPP. INFECTIONS 
Results 
Artifacts of assays 
All bacteria, including Ureaplasma, with at least two molecular tests available (Table 4) 
were not frequently detected in both blood and respiratory specimens, i.e. concordance between 
respiratory and blood detections was low.  Six (19%) of the 31 blood specimens positive for 
Ureaplasma were also positive on respiratory TAC, and 1% of respiratory specimens were also 
positive on blood TAC.  Among those speciated (n=498), 57% were U. parvum, 31% were U. 
urealyticum, 4% were both species, and 8% could not be speciated.  
Observed diagnostic results 
Ureaplasma spp. were detected in higher numbers in infants with suspected infection 
compared to healthy infants.  Crude odds ratios (cORs) varied by specimen type and study site, 
ranging from 1.5 to 2.7.  When stratified by age at onset of disease, cORs were higher for infants 
with early onset disease.  Among infants who died, cORs were 3.7 for respiratory specimens and 
1.4 for blood specimens.  Furthermore, the Ureaplasma detections were not limited to preterm 
infants. The cORs for Ureaplasma was higher among term infants than preterm infants (1.8 vs. 
1.6 in respiratory specimens; 1.5 and 1.3 for blood specimens).7   
Criteria for which ANISA modeled results are less reliable 
Ureaplasma did not fall into any of the documented pLCM “danger zones”. Ureaplasma 
was included in both the respiratory and blood molecular PCR TAC, so there were two test 
results available for every case.  The overall cOR was > 1 for respiratory specimens in all study 
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sites, and >1 in 3 of the 5 study sites for blood specimens (the two Indian sites had cOR <1 in 
blood).  The Ureaplasma population proportion was 2.8% (95% CI: 1.9%, 3.8%), the second 
highest in the study after RSV.  The mean false positive rates (FPRs) ranged from 3.1% (95% 
CI: 2.1%, 4.21%) in Matiari to 12.6% (95% CI: 11.2%, 13.8%) in Odisha for respiratory 
specimens, and from 0.1% (95% CI: 0.1%, 0.23%) in Karachi to 0.4% (95% CI: 0.2%, 0.6%) in 
Sylhet for blood specimens. 7  The specificity was low and similar to those for other pathogens.  
Sensitivity (constant across sites) was 61.5% (95%CI: 48.3%, 76.2%) for the respiratory 
molecular test and 22.2% (95%CI: 20.1%, 27.6%) for the blood molecular assay, both above all 
specificity estimates. 
Ureaplasma as commensal organism vs pathogen causing illness 
Overall, 26% of healthy infants and 28% of Ureaplasma attributable cases had nothing 
other than Ureaplasma detected in either blood or respiratory specimens (Table 5).  A few 
pathogens (group A Streptoccocus and Mycoplasma pneumoniae, and viruses influenza B, 
parainfluenza virus 3, and RSV) were more common in Ureaplasma attributable infants vs 
healthy infants, but the differences in proportions were small.  . 
Based on the ANISA pLCM results, 68 cases had an average individual Ureaplasma 
probability > 50% (Table 6).  In this subset, 73.7% (95%CI: 51.9%, 100.0%) of infants had 
illness attributable to Ureaplasma, and 22.2% (95%CI: 0%, 46.7%) had no identifiable infectious 
etiology.  Only E. coli had an average individual probability of 1% or greater in this population.  
After removing the Ureaplasma etiologic contribution in this subset, 83.3% (95%CI: 13.1%, 
97.0%) of the population had no infectious etiology identified;85% of the Ureaplasma 
contribution did not assign to any other pathogen once set to zero, while the remaining 15% of 
the individual case probabilities were re-distributed among E. coli (3.1% (95%CI: 0,57%.7%)), 
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Streptococcus pneumoniae (2.6% (95%CI: 0,66%.9%)), other bacteria identified by blood 
culture (2.4% (95%CI: 0%,15.3%)), Klebsiella pneumoniae (1.7% (95%CI: 0%,44.8%)), 
Cytomegalovirus (1.7% (95%CI: 0%,61.7%), and Bordetella sp. (1.3% (95%CI: 0%,80.9%).  
After Ureaplasma’s contribution was removed from this population, Bordetella sp., E. coli, 
Streptococcus pneumoniae, and Cytomegalovirus average individual probabilities were higher 
than the population probabilities estimated in the primary etiology study, and of these, E. coli, 
Streptococcus pneumoniae, and Cytomegalovirus averages were higher than the upper credible 
interval limit of these estimated probabilities. 
Describing deaths among infants with Ureaplasma-attributable illness 
The overall distribution of average individual Ureaplasma probabilities among those who 
survived is more heavily right skewed (skewness=2.09) than for those who died (skewness=1.19) 
(Figure 8).  The median individual Ureaplasma probability was 2 times as high among infants 
who died (15%) when compared to cases who survived (7%) (p-value <0.0001).   Among infants 
with Ureaplasma attributable illness, 27.2% (95%CI: 21.2%, 34.5%) were hospitalized, and 
22.7% (95%CI: 15.5%, 30.3%) died (Tables 7 and 8). In comparison, 29% of infants who met 
the ANISA case definition were hospitalized, and 13% of them died.7 
Characteristics of infants with Ureaplasma attributable illness 
Over a third (38.3%) of mothers with infants who were among the Ureaplasma 
attributable population, had attended school at any time, and 3.8% were under the age of 20 
years at the time of delivery (Tables 7 and 8).  The proportion of mothers with at least 1 antenatal 
care visit was 77.8% (95%CI: 73.4%, 81.3%), 44.6% (95%CI: 38.9%, 50.9%) received the full 
antenatal package, and 9.1% (95%CI: 7.4%, 10.6%) had measured poor nutritional status.  Few 
mothers died (0.02% (95%CI: 0.0%, 0.04%)). 
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Among infants with Ureaplasma attributable illness, 57.2% (95%CI: 54.3%, 60.0%) 
were male, 22.0% (95%CI: 19.2%, 24.8%) were preterm, and 50.0% (95%CI: 46.1%, 53.7%) of 
them were low birthweight.  Among infected infants, the most common danger signs observed 
were poor feeding (39.8% (95%CI: 33.9%, 46.0%)), fast breathing (39.1% (95%CI: 35.7%, 
42.2%)), and fever (34.1% (95%CI: 29.1%, 38.6%)).   
Infants with early onset illness had significantly higher proportions of complications or 
illness since birth (50.2% (95%CI: 46.7%, 54.0%)) when compared with infants with late onset 
illness 20.7% (95%CI: 17.3%, 24.3%) (Table 4a).  The only significant difference in clinical 
danger signs was the higher proportion of preterm infants with poor feeding (53.1% (95%CI: 
44.5%, 61.9%)) when compared to term infants (36.8% (95%CI: 30.8%, 43.0%)).  As expected, 
no infant in the Ureaplasma attributable population was treated with appropriate antibiotics. Of 
all of the hospitalization episodes recorded in the ANISA cohort (n=2344), tetracycline and 
doxycycline were never prescribed, and erythromycin, clindamycin, and clarithromycin were 
prescribed less than twice each.  Azithromycin was prescribed less than 2% of the time (n=43).  
Discussion 
We were unable to identify a viable alternative explanation for the ANISA Ureaplasma 
finding.  Furthermore, ANISA describes the infant population with Ureaplasma attributable 
illness as having different clinical characteristics than what has previously been described in the 
literature. ANISA is one of the first studies of its kind to implement molecular diagnostics in 
addition to traditional blood culture methods, and to employ modeling strategies incorporating 
all diagnostic evidence to improve estimates of neonatal illness etiology.  Given the diagnostic 
challenges with growing Ureaplasma on culture and lack of access to advance molecular 
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diagnostic tools, this has likely led to Ureaplasma previously being underdetected in the clinical 
setting.   
Among respiratory specimens (the source of the majority of Ureaplasma detections), 
Ureaplasma detections were more common among cases than healthy infants in every study site.  
The differences in Ureaplasma detections between sick and healthy infants was even higher 
among term infants than in preterm infants, whereas Ureaplasma has been described in the 
literature as being an infection in preterm infants.  Importantly, 93% of all respiratory or blood 
specimens positive for Ureaplasma in the ANISA study were speciated to either U. parvum, U. 
urealyticum, or both, confirming that the diagnostic results were not an artifact of the TAC 
assays.  While concordance was low between blood and respiratory specimens, the lower 
concordance would only drive the population proportion lower, not higher, than other pathogens 
with higher concordance. 
The proportions of detections of other bacteria and viruses between healthy infants and 
Ureaplasma attributable cases were similar, with few significant differences for a handful of 
organisms.  The proportion of infants with nothing other than Ureaplasma identified were also 
similar between the two groups.  Taking a step further and examining illness attribution using the 
ANISA pLCM model without Ureaplasma’s contribution in the population, the majority (85%) 
of Ureaplasma’s contribution was re-distributed to the “no identifiable infectious etiology” 
category, with the rest of Ureaplasma’s contribution re-distributed to a handful of bacteria.  Only 
E. coli, S. pneumoniae and Cytomegalovirus average probabilities increased above the upper 
confidence limits estimated in the primary ANISA etiology study.  These data suggest there was 
no other organism was co-detected frequently enough, or whose attribution proportion rose 
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sharply once Ureaplasma was removed from the population, to suggest that Ureaplasma was a 
commensal organism found in conjunction with another pathogen causing disease.   
The description of the infant population with Ureaplasma attributed illness highlighted 
how different this population is from infants with Ureaplasma illness described previously in the 
literature.  The literature describes extremely and very preterm infants with Ureaplasma 
infection, with clinical presentation manifesting as bronchopulmonary dysplasia, sepsis, and mild 
cerebral impairment.  There were similar numbers of preterm infants with Ureaplasma 
attributable illness (22% vs 20%) when compared to the entire enrolled population, and less than 
3% of them were extremely or very preterm.  A higher proportion of infants with Ureaplasma 
attributable illness (24%) died when compared with all infants who met the case definition 
(13%), and the median average individual Ureaplasma probability was 2 times as high among 
deaths (15%) when compared to cases who survived (7%).  These findings suggest that 
Ureaplasma causes severe disease, or infants with Ureaplasma attributable illness had more 
severe outcomes due to treatment with antibiotics that are not effective against this agent, or 
both.    
While there have been several studies describing the relationship between Ureaplasma 
colonization (detection in asymptomatic individuals) and adverse maternal and neonatal 
outcomes, these findings have been limited to preterm infants. 31-33 Only one study has found 
placental infection with Ureaplasma spp. associated with chorioamnionitis regardless of 
gestational age, and further adverse outcomes (requiring oxygen or positive pressure respiratory 
support for prolonged periods) in those infants that were moderate to late preterm. 34 There is one 
case report in the literature that describes late onset meningitis in a full term newborn caused by 
Ureaplasma parvum in the United States.35 
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A recent etiology study conducted in Soweto, South Africa, using a very similar protocol 
and diagnostic methods to the ANISA study, reported Ureaplasma as the most important 
pathogen causing neonatal illness in their study population.  They reported a Ureaplasma 
incidence rate of 2.11 per 1,000 live births, which represents 5.4% of the study population were 
Ureaplasma attributable cases.  Notably, over half (52.7%) of the infants in the study population 
were term (=>37 weeks). 
There were limitations to our study.  As in the primary ANISA etiology study, the 
ANISA case definition is very sensitive and not specific, potentially leading to misclassification 
of infants. Blood culture was the ‘gold’ standard within the ANISA study—having a blood 
culture positive increased the probability of attribution to that pathogen.  As Ureaplasma does 
not grow in standard blood culture media, there were no Ureaplasma isolated from blood culture 
in this study.  The lack of blood culture results is one possible theory for the vast majority of the 
individual probabilities for Ureaplasma etiology being less than 10%, despite crude ORs above 
1.  Even with this limitation, Ureaplasma was the second highest estimated population 
proportion in the study. While some analyses presented here have a small sample size, these are 
the first data that describe term infants with Ureaplasma attributable illness.   
Ureaplasma has not been identified previously as a relevant pathogen for young infants, 
and the current WHO recommended regimens (typically gentamicin or amoxicillin) would not be 
effective against this agent.  Any future studies investigating Ureaplasma as a causative agent of 
illness in neonates, as well as the relationship between the presence of Ureaplasma with preterm 
and low birthweight infants, should use diagnostics that will allow for the detection of 
Ureaplasma.  Further research would inform whether changes to current antibiotic regimens 
recommended by WHO for treatment of ill neonates are needed. 
  
51 
Table 4. Distribution of detectionsin blood and respiratory specimens tested by TaqMan 
Array (TAC) for bacteria with assays on both cards, Aetiology of Neonatal Infections in 
South Asia (ANISA) Study, 2011-2014 
Bacteria Total number 
















% infants with 
detections in 











   group B 
Streptoccocus 
550 25 10 29% 2% 
   Escherichia coli 1824 107 42 28% 2% 
   Klebsiella 
pneumoniae 
1571 110 42 28% 3% 
   Streptococcus 
pneumoniae 
2471 81 54 40% 2% 
   Ureaplasma sp. 684 25 6 19% 1% 
1 A positive detection in a sick infant is defined by a positive result on a TAC card from either respiratory or blood 
specimens.  Group B Streptococcus, Eschericia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, and 




Table 5. Pathogen detections by TaqMan PCR in either blood or respiratory specimens1 in 
healthy infants and Ureaplasma attributable cases, Aetiology of Neonatal Infections in 
South Asia (ANISA) Study, 2011-2014 
 Number of 
detections among 
healthy infants 2 
N=1894 
# (%) 
Mean number of detections 
among cases with Ureaplasma 





None 5 496 (26) 43 (28) 0.67 
Bordetella spp. 73 (4) 7 (4) 0.68 
Chlamydia trachomatis 5 (0.3) 1 (1) 0.40 
Chlamydia pneumoniae 3 (0.2) 1 (1) 0.19 
group A Streptococcus 0 1 (1) 0.0004 
group B Streptococcus 126 (7) 13 (8) 0.41 
Eschericia coli 482 (26) 39 (26) 0.94 
Haemophilus influenzae 6 (0.3) 2 (1) 0.06 
Klebsiella pneumoniae 444 (23) 33 (22) 0.54 
Mycoplasma pneumoniae 1 (0.1) 1 (1) 0.02 
Neisseria meningitidis 4 (0.2) 1 (1) 0.29 
Pseudomonas aeruginosa 7 (0.4) 1 (1) 0.60 
Streptococcus pneumoniae 638 (34) 55 (35) 0.64 
Salmonella spp. 30 (2) 3 (2) 0.74 
Staphyloccocus aureus 15 (0.8) 2 (1) 0.51 
Adenovirus 34 (2) 2 (1) 0.65 
Cytomegalovirus 153 (8) 12 (8) 0.88 
Influenza A 13 (0.7) 2 (1) 0.40 
Influenza B 3 (0.2) 2 (1) 0.006 
Human metapneumovirus 6 (0.3) 1 (1) 0.50 
Human parechovirus 12 (0.6) 2 (1) 0.34 
Parainfluenza virus 1 7 (0.4) 2 (1) 0.09 
Parainfluenza virus 2 16 (0.8) 1 (1) 0.79 
Parainfluenza virus 3 0 3 (2) < .00001 
Respiratory synctitial virus 25 (1) 12 (8) < .00001 
Rhinovirus/Enterovirus 644 (34) 45 (29) 0.21 
Rubella 5 (0.3) 2 (1) 0.03 
1 A positive detection in a case is defined by a positive result on a TAC card from either respiratory or blood specimens.  
Adenovirus, Bordetella sp., Chlamydia trachomatis, Chlamydia pneumoniae, Cytomegalovirus, Human metapneumovirus, 
Human parechovirus, Influenza A, Influenza B, Mycoplasma pneumoniae, Parainfluenza virus 1, Parainfluenza virus 2, 
Parainfluenza virus 3, Respiratory synctitial virus (RSV), Rhinovirus/Enterovirus, and Rubella assays were included on the 
respiratory TAC respiratory only. group A Streptococcus, Haemophilus influenzae, Neisseria meningitidis, Pseudomonas 
aeruginosa, Salmonella spp., and Staphyloccocus aureus assays were included on the blood TAC only. group B Streptococcus, 
Eschericia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, and Ureaplasma spp. assays were included on both the 
respiratory and blood TACs. 
2 A healthy infant is an infant with clinical specimens and results who did not meet the case definition at the time of specimen 
collection.   
3 An ANISA case is defined as infant between 0 and 59 days of age that presented with one of the following signs, as 
confirmed by a physician:  respiratory rate >=60/minute (fast breathing), severe chest in-drawing, axillary temperature either 
=>38°C (fever) or <35.5°C (hypothermia), movement only when stimulated or no movement at all, convulsions, or not feeding 
well confirmed on observation by study personnel.   
4 Ureaplasma attributable cases is defined as an individual infant who met the ANISA case definition, with a probabilistic 
assignment of Ureaplasma as the causative agent of illness, based on the estimated partial latent class model(pLCM) results.  
5 None is defined as having no other detections in either respiratory or blood specimens other than Ureaplasma sp.    
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Table 6. Distribution of average individual pathogen attribution probabilities for infant 
cases1 both with and without Ureaplasma included, limited to infant cases with an average 
individual Ureaplasma probability >50%, Aetiology of Neonatal Infections in South Asia 





% (95% CI) 





% (95% CI) 
Bordetella sp. 0.1 (0,6.8) 1.3 (0,80.9) 
Chlamydia pneumoniae 0 (0,0) 0 (0,0.5) 
Chlamydia trachomatis 0 (0,0.1) 0.1 (0,0.5) 
Escherichia coli 1.1 (0,2.6) 3.1 (0,57.7) 
Group A Streptococcus 0 (0,0.2) 0 (0,0) 
Group B Streptococcus 0.1 (0,0.6) 0 (0,1.6) 
Klebsiella pneumoniae 0.6 (0,17.9) 1.7 (0,44.8) 
Mycoplasma pneumoniae 0 (0,0) 0 (0,0) 
Neisseria meningitidis 0 (0,0.1) 0 (0,0.6) 
Haemophilus influenzae 0.1(0,0.8) 0 (0,1.9) 
Pseudomonas aeruginosa 0.1 (0,1.5) 0 (0,3.8) 
Salmonella sp. 0.2 (0,2.1) 0.7 (0,6.8) 
Staphyloccocus aureus 0.2 (0,1.0) 0.8 (0,2.9) 
Streptococcus pneumoniae 0.5 (0,10.8) 2.6 (0,66.9) 
Ureaplasma sp. 73.7 (51.9,100.0) 0 (0,0) 
Other Blood Culture 0.7 (0,6.5) 2.4 (0,15.3) 
Adenovirus 0 (0,0.1) 0.1 (0,2.5) 
Cytomegalovirus 0.2 (0,7.1) 1.7 (0,61.7) 
Enterovirus / Rhinovirus 0.2 (0,3.3) 0.8 (0,12.1) 
Human metapneumovirus 0 (0,0.8) 0.1 (0,4.0) 
Human parechovirus 0 (0,0) 0 (0,0) 
Influenza A 0.0 (0.0,0.0) 0 (0,1.7) 
Influenza B 0 (0,0.5) 0.1 (0,1.4) 
Parainfluenza virus type 1 0 (0,0.6) 0.2 (0,2.5) 
Parainfluenza virus type 2 0 (0,0.1) 0 (0,0.3) 
Parainfluenza virus type 3 0 (0,0.2) 0.1 (0,4.3) 
Respiratory syncytial virus 0 (0,0.9) 0.2 (0,4.4) 
Rubella 0 (0,0.1) 0 (0,0.4) 
No etiology identified 22.2 (0,46.7) 83.3(0,97.4) 
1An ANISA case is defined as infant between 0 and 59 days of age that presented with one of the following signs, as 
confirmed by a physician:  respiratory rate >=60/minute (fast breathing), severe chest in-drawing, axillary 
temperature either =>38°C (fever) or <35.5°C (hypothermia), movement only when stimulated or no movement at 
all, convulsions, or not feeding well confirmed on observation by study personnel.   
2 An average individual probability is the likelihood from the ANISA pLCM model that a given organism is the 
causative agent of illness for a given case. 
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Table 7. Demographic and clinical characteristics of young Ureaplasma attributable cases1, 
stratified by early and late onset of disease, Aetiology of neonatal Infections in South Asia 











Characteristic     
Maternal    
   First live birth 29.3 (22.6, 35.9) 29.7 (25.4, 34.6) 29.5 (25.0, 34.4) 
   Ever attended school  34.3 (24.0, 45.8) 41.5 (33.6, 50.4) 38.3 (30.2, 47.2) 
   Maternal age <20 years at delivery 4.4 (1.9, 7.3) 3.3 (2.1, 4.9) 3.8 (2.3, 5.7) 
   Pregnancy    
       High grade fever during pregnancy 22.6 (17.7, 27.4) 15.4 (11.4, 19.4) 18.7 (14.9, 22.2) 
       High grade fever within 7 days of 
delivery 
17.2 (13.1, 21.2) 11.9 (8.5, 15.1) 14.4 (11.1, 17.3) 
       Any complications during pregnancy 4 9.1 (6.8, 11.6) 2.6 (1.6, 3.7) 5.6 (4.4, 6.7) 
       At least 1 antenatal care visit with skilled    
provider 5 
78.5 (73.8, 82.8) 77.3 (72.2, 81.4) 77.8 (73.4, 81.3) 
       Poor nutritional status 6 10.7 (8.7, 13.1) 7.6 (5.1, 10.1) 9.1 (7.4, 10.6) 
       Received full antenatal package 7 41.3 (34.4, 48.5) 47.3 (40.8, 54.9) 44.6 (38.9, 50.9) 
    Labor/delivery    
       Delivery at health facility 8 61.5 (50.6, 71.3) 59.1 (50.2, 67.4) 60.2 (50.9, 67.6) 
       Skilled birth attendant 5 63.1 (53.4, 71.4) 60.9 (52.8, 68.5) 61.9 (54.0, 68.5) 
       Clean delivery kit 68.8 (57.1, 78.2) 64.5 (55.8, 72.0) 66.5 (57.4, 73.7) 
       Duration of ruptured membrane > 12 
hours 
27.9 (23.0, 32.8) 21.2 (17.2, 25.4) 24.3 (20.7, 27.6) 
       Foul smelling discharge during 
labor/delivery 
24.1 (19.1, 28.7) 16.8 (12.7, 20.3) 20.2 (16.1, 23.6) 
       Any other complication during 
labor/delivery 9 
25.9 (22.5, 29.6) 18.3 (15.1, 21.6) 21.8 (19.2, 24.6) 











Infant    
   Male 55.8 (51.0, 60.6) 58.4 (54.7, 62.5) 57.2 (54.3, 60.0) 
   Preterm 10 23.5 (19.2, 27.9) 20.5 (17.2, 24.0) 22.0 (19.2, 24.8) 
   Low birthweight11 53.5 (49.4, 57.8) 46.8 (41.7, 52.1) 50.0 (46.1, 53.7) 
   Proper tying and cutting of umbilical cord 12 53.5 (47.0, 59.4) 61.1 (54.5, 66.6) 57.6 (52.0, 62.4) 
   Proper application of antibiotic/antiseptic to 
umbilical cord 13 
44.7 (36.3, 53.0) 46.2 (38.8, 54.0) 45.5 (38.4, 52.1) 
   Delayed breathing or crying after birth 14 20.3 (15.0, 25.1) 14.4 (11.1, 17.8) 17.2 (13.7, 20.2) 
   Ever initiated breastfeeding 77.0 (70.2, 82.5) 91.4 (89.3, 93.6) 84.7 (81.2, 87.9) 
   Given colostrum 43.9 (34.1, 55.3) 60.3 (51.6, 69.7) 52.8 (44.4, 61.9) 
   Any supplementation in first 3 days of life 29.4 (22.9, 36.4) 35.7 (28.0, 43.2) 32.8 (26.3, 38.9) 
   Any complications or illness since birth 50.2 (46.7, 54.0) 20.7 (17.3, 24.3) 34.4 (30.9, 37.9) 
   Integrated Management of Childhood 
Infection Signs 
   
      Respiratory rate >=60 breaths per minute 47.6 (43.9, 51.2) 31.8 (27.2, 36.1) 39.1 (35.7, 42.2) 
      Severe chest in-drawing 10.5 (7.1, 14.0) 28.9 (23.0, 34.8) 20.4 (16.7, 24.4) 
      Axillary temperature >38.0`C (>100.4`F) 35.0 (27.3, 42.1) 33.6 (29.2, 38.2) 34.1 (29.1, 38.6) 













     Movement only when stimulated or no  
     movement 
21.3 (16.6, 26.5) 16.3 (12.3, 21.3) 18.6 (14.7, 22.8) 
     Convulsions (confirmed by observation) 6.3 (4.2, 8.7) 2.7 (1.5, 4.1) 4.4 (3.1,5.8) 
     Poor feeding (confirmed by observation) 55.6 (49.5, 62.2) 26.2 (20.6, 33.0) 39.8 (33.9, 46.0) 
   Other clinical signs    
     Apnea 7.0 (3.7, 10.7) 2.2 (1.5, 3.5) 4.4 (2.8, 6.4) 
     Cyanosis 13.1 (9.0, 17.9) 3.7 (2.1, 5.8) 8.1 (5.8, 10.8) 
     Bulging fontanelle 0.8 (0.2, 1.7) 0.5 (0.02, 0.7) 0.6 (0.3, 1.0) 
     Unable to cry 17.5 (11.8, 24.2) 8.4 (6.0, 11.1) 12.6 (9.3, 15.6) 
     Prolonged capillary refill 1.5 (0.2, 3.0) 0.2 (0.03, 0.5) 0.8 (0.1, 1.5) 
     Skin pustules 1.9 (1.0, 2.8) 8.0 (6.1, 10.2) 5.1 (4.1, 6.4) 
     Umbilical pus or redness 9.2 (6.6, 11.8) 6.7 (5.1, 8.7) 7.9 (6.3, 9.4) 
   Child Hospitalized 30.2 (23.0, 39.7) 24.6 (18.4, 31.8) 27.2 (21.2, 34.5) 
   Child Died 26.2 (14.6, 37.9) 19.6 (14.2, 26.2) 22.7 (15.5, 30.3) 
1 Ureaplasma attributable cases is defined as an individual infant who met the ANISA case definition, with a probabilistic 
assignment of Ureaplasma as the causative agent of illness, based on the estimated pLCM model results.  
2 Early onset is defined as illness in infants <3 days; late-onset is defined as illness in infants =>3 days of age and less than or 
equal to 59 days of age 
3 Lower credible limit, Upper credible limit 
4 Any complications during pregnancy is defined as having one of the following complications: high grade fever, foul smelling 
discharge, swelling of face or feet, excessive bleeding, or convulsions. 
5 A skilled provider or skilled birth attendant is defined as a qualified doctor, nurse, midwife, or paramedic. 
6 Poor nutritional status defined as mid upper arm circumference of less than 21.5 centimeters. 
7 Received full antenatal package defined as: 1. receipt of at least 2 antenatal visits from a community health worker; AND 2. 
Receipt of 2 tetanus injections during current pregnancy, OR 1 tetanus injection and at least 4 shots pre-pregnancy, OR at least 5 
tetanus injections pre-pregnancy; AND 3. Receipt of at least one iron tablet or dose or iron syrup during current pregnancy.   
8Delivery at a health facility is defined as being born at a public or private hospital, a maternity center, or clinic. 
9 Any other complication during labor/delivery is defined as excessive bleeding, convulsions, retained placenta, abnormal 
presentation, prolonged labor, or premature water breaking. 
10 Preterm is defined as an infant born <37 weeks gestational age; Term is defined as an infant born at  => 37 weeks or greater. 
11 Low birth weight is defined as an infant weighing <2500 g at birth. 
12 Proper tying and cutting of umbilical cord is defined as use of an acceptable device for both cutting and tying the umbilical 
cord.  Acceptable devices for cutting cords in the home must be boiled and be either thread, clip kit, knife, blade, or tongs.  
Acceptable devices for cutting cords in a hospital or health facility should be nurse/doctor’s scissor or clip kit.  Acceptable 
devices for tying cord in the home must be boiled and be either a clip, clip kit, thin rope brought by doctor, blade, or rubber band.  
Acceptable devices for tying a cord in a hospital or health facility is a clip or clip kit.   
13 Proper application of antibiotic or antiseptic to the umbilical cord differs by setting.  In the home, antibiotic or antiseptic must 
be applied to the stump.  In the hospital, antibiotic or antiseptic can be applied, or nothing can be applied. 




Table 8. Demographic and clinical characteristics of young Ureaplasma attributable cases1, 












Characteristic     
Maternal    
   First live birth 30.8 (22.9, 38.6) 32.4 (27.7, 37.2) 29.5 (25.0, 34.4) 
   Completed secondary school 42.7 (33.1, 52.3) 41.0 (32.9, 50.2) 38.3 (30.2, 47.2) 
   Maternal age <20 years at delivery 5.1 (2.3, 8.2) 3.9 (2.4, 5.7) 3.8 (2.3, 5.7) 
   Pregnancy    
       High grade fever during pregnancy 23.3 (16.3, 30.2) 17.1 (13.5, 20.6) 18.7 (14.9, 22.2) 
       High grade fever within 7 days of 
delivery 
15.8 (10.8, 21.2) 12.8 (9.9, 15.5) 14.4 (11.1, 17.3) 
       Any complications during pregnancy 4 6.1 (3.9, 8.5) 5.8 (4.4, 7.2) 5.6 (4.4, 6.7) 
       At least 1 antenatal care visit with skilled    
provider 5 
75.9 (67.9, 82.7) 78.1 (74.2, 81.6) 77.8 (73.4, 81.3) 
       Poor nutritional status 6 11.9 (8.1, 16.6) 9.4 (7.6, 11.2) 9.1 (7.4, 10.6) 
       Received full antenatal package 7 45.8 (36.7, 54.8) 48.0 (42.3, 54.2) 44.6 (38.9, 50.9) 
    Labor/delivery    
       Delivery at health facility 8 59.7 (47.5, 71.1) 60.7 (51.3, 68.7) 60.2 (50.9, 67.6) 
       Skilled birth attendant 5 61.6 (50.1, 72.0) 62.2 (54.0, 69.2) 61.9 (54.0, 68.5) 
       Clean delivery kit 64.6 (50.6, 75.9) 66.7 (57.9, 73.4) 66.5 (57.4, 73.7) 
       Duration of ruptured membrane > 12 
hours 
22.9 (17.3, 29.2) 24.8 (21.0, 28.6) 24.3 (20.7, 27.6) 
       Foul smelling discharge during 
labor/delivery 
19.7 (14.8, 24.5) 19.8 (15.8, 23.5) 20.2 (16.1, 23.6) 
       Any other complication during 
labor/delivery 9 
17.5 (13.3, 21.9) 22.6 (19.7, 26.0) 21.8 (19.2, 24.6) 











Infant    
   Male 52.2 (44.6, 59.1) 57.0 (54.0, 60.0) 57.2 (54.3, 60.0) 
   Early onset illness 11 49.7 (38.9, 59.2) 44.4 (37.5, 50.8) 22.0 (19.2, 24.8) 
   Low birthweight12 70.2 (64.1, 76.4) 42.3 (38.7, 46.4) 50.0 (46.1, 53.7) 
   Proper tying and cutting of umbilical cord 
13 
58.6 (50.7, 66.0) 57.0 (50.8, 62.3) 57.6 (52.0, 62.4) 
   Proper application of antibiotic/antiseptic     
   to umbilical cord 14 
42.0 (31.4, 52.8) 46.3 (39.1, 53.4) 45.5 (38.4, 52.1) 
   Delayed breathing or crying after birth15 20.2 (14.8, 26.1) 15. 0 (11.6, 18.2) 17.2 (13.7, 20.2) 
   Ever initiated breastfeeding 79.1 (70.5, 86.4) 85.9 (83.0, 88.7) 84.7 (81.2, 87.9) 
   Given colostrum 51.5 (40.5, 63.4) 55.5 (47.2, 64.3) 52.8 (44.4, 61.9) 
   Any supplementation in first 3 days of life 31.6 (23.3, 40.8) 31.5 (25.0, 38.0) 32.8 (26.3, 38.9) 
   Any complications or illness since birth 32.6 (25.5, 40.3) 33.2 (29.0, 37.3) 34.4 (30.9, 37.9) 
   Integrated Management of Childhood  
   Infection Signs 
   
     Respiratory rate >=60 breaths per minute 36.4 (31.0, 41.8) 39.4 (35.2, 43.5) 39.1 (35.7, 42.2) 
     Severe chest in-drawing 14.9 (8.9, 21.8)) 23.2 (18.8, 27.8) 20.4 (16.7, 24.4) 













     Axillary temperature <35.5`C (<95.9`F) 20.7 (13.6, 27.3) 13.7 (10.5, 16.8) 17.3 (13.4, 20.8) 
     Movement only when stimulated or no  
     movement 
24.4 (16.8, 32.6) 16.5 (12.9, 20.4) 18.6 (14.7, 22.8) 
     Convulsions (confirmed by observation) 2.4 (0.9, 4.4) 5.5 (3.8, 7.2) 4.4 (3.1,5.8) 
     Poor feeding (confirmed by observation) 53.1 (44.5, 61.9) 36.8 (30.8, 43.0) 39.8 (33.9, 46.0) 
   Other clinical signs    
     Apnea 4.3 (1.9, 8.3) 5.0 (3.0, 7.0) 4.4 (2.8, 6.4) 
     Cyanosis 10.4 (5.1, 15.7) 7.3 (5.1, 9.7) 8.1 (5.8, 10.8) 
     Bulging fontanelle 0.6 (0.2, 1.1) 0.7 (0.3, 1.3) 0.6 (0.3, 1.0) 
     Unable to cry 16.7 (10.8, 24.9) 11.1 (7.8, 14.7) 12.6 (9.3, 15.6) 
     Prolonged capillary refill 0.7 (0.05, 2.4) 0.9 (0.2, 1.7) 0.8 (0.1, 1.5) 
     Skin pustules 5.8 (3.8, 8.5) 4.5 (3.3, 5.9) 5.1 (4.1, 6.4) 
     Umbilical pus or redness 7.1 (4.0, 10.7) 8.0 (6.5, 9.6) 7.9 (6.3, 9.4) 
   Child Hospitalized 28.8 (19.7, 39.8) 28.1 (22.1, 35.4) 27.2 (21.2, 34.5) 
   Child Died 28.6 (16.7, 41.8) 20.7 (14.2, 27.3) 22.7 (15.5, 30.3) 
1 Ureaplasma attributable cases is defined as an individual infant who met the ANISA case definition, with a probabilistic 
assignment of Ureaplasma as the causative agent of illness, based on the estimated pLCM model results.  
2 Preterm is defined as an infant born <37 weeks gestational age; Term is defined as an infant born at  => 37 weeks or greater 
3 Lower credible limit, Upper credible limit 
4 Any complications during pregnancy is defined as having one of the following complications: high grade fever, foul smelling 
discharge, swelling of face or feet, excessive bleeding, or convulsions. 
5 A skilled provider or skilled birth attendant is defined as a qualified doctor, nurse, midwife, or paramedic. 
6 Poor nutritional status defined as mid upper arm circumference of less than 21.5 centimeters. 
7 Received full antenatal package defined as: 1. receipt of at least 2 antenatal visits from a community health worker; AND 2. 
Receipt of 2 tetanus injections during current pregnancy, OR 1 tetanus injection and at least 4 shots pre-pregnancy, OR at least 5 
tetanus injections pre-pregnancy; AND 3. Receipt of at least one iron tablet or dose or iron syrup during current pregnancy.   
8 Delivery at a health facility is defined as being born at a public or private hospital, a maternity center, or clinic. 
9 Any other complication during labor/delivery is defined as excessive bleeding, convulsions, retained placenta, abnormal 
presentation, prolonged labor, or premature water breaking. 
10 N=288 infants had missing gestational age; 2 of the 4 mothers who died had infants with missing gestational age. 
11 Early onset is defined as illness in infants <3 days; late-onset is defined as illness in infants =>3 days of age and less than or 
equal to 59 days of age 
12 Low birth weight is defined as an infant weighing <2500 g at birth. 
13 Proper tying and cutting of umbilical cord is defined as use of an acceptable device for both cutting and tying the umbilical 
cord.  Acceptable devices for cutting cords in the home must be boiled and be either thread, clip kit, knife, blade, or tongs.  
Acceptable devices for cutting cords in a hospital or health facility should be nurse/doctor’s scissor or clip kit.  Acceptable 
devices for tying cord in the home must be boiled and be either a clip, clip kit, thin rope brought by doctor, blade, or rubber band.  
Acceptable devices for tying a cord in a hospital or health facility is a clip or clip kit.   
14 Proper application of antibiotic or antiseptic to the umbilical cord differs by setting.  In the home, antibiotic or antiseptic must 
be applied to the stump.  In the hospital, antibiotic or antiseptic can be applied, or nothing can be applied. 




Figure 8. Distribution of average individual probabilities1 of Ureaplasma infection among 
all cases2 meeting the ANISA case definition, stratified by survived and died, Aetiology of 
Neonatal Infections in South Asia (ANISA) Study, 2011-14 
 
1 An average individual probability is the likelihood from the ANISA pLCM model that a given organism is the causative agent 
of illness for a given case.  
2An ANISA case is defined as infant between 0 and 59 days of age that presented with one of the following signs, as confirmed 
by a physician:  respiratory rate >=60/minute (fast breathing), severe chest in-drawing, axillary temperature either =>38°C (fever) 
or <35.5°C (hypothermia), movement only when stimulated or no movement at all, convulsions, or not feeding well confirmed 






CHAPTER 6: DISCUSSION 
Defining etiology of illness is a challenging field of study, and even more so in neonates 
as their symptoms are non-specific.   Given the paucity of data on etiology of neonatal infection, 
especially in low resource settings where neonatal mortality is high, the ANISA study sought 
describe the etiologic agents of neonatal infection.  The ANISA study was conducted in 
countries with relatively high burden of neonatal disease and mortality, and high rates of refusal 
of referral for treatment/hospitalization, thereby providing the appropriate population to describe 
vital data on the etiologic spectrum of disease in young infants.   
A large proportion of illness did not have an infectious etiology identified.  Given this 
level of potential misclassification, our secondary objective was to estimate the prevalance of 
pathogens in three different subsets of infants meeting the WHO case definitions of critically ill, 
clinical severe infection, and isolated fast breathing in infants ages 3-59 days, in order to 
quantify if the more severe classifications were better at capturing infants with bacterial 
infection.  We calculated the prevalence for every sign in the WHO case definition among 
infants meeting the clinical severe case definition to understand if any one danger sign was better 
at predicting infection. The data suggest it would be difficult to develop a clinical algorithm to 
distinguish bacterial from viral infections. Furthermore, we found none of the case definitions 
evaluated here distinguish well between identifiable infectious and non-identifiable causes of 
illness. While infants are likely being unnecessarily treated with antibiotics in these settings, 
given they meet the case definition but may have a viral etiology or no infectious etiology at all, 
there are infectious etiologies found even among the least severely ill infants. These data suggest 
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that there may be a substantial proportion of illness for which other interventions would be more 
effective, or there may be a number of unidentified pathogens causing illness. 
While the proportion of infants with a bacterial etiology was highest in the most severe 
category, and lowest in the least severe category, there was still a non-zero proportion of those 
with bacterial etiology in every category.   If the trials conducted in Africa and South Asia that 
evaluated the equivalency of simpler antibiotic regimens to the conventional regimens 46,47,49 had 
limited their study population to those with a bacterial etiology, simplified regimens may not 
have performed as well.  However, in the absence of a method available to identify etiology of 
illness more readily in low resource settings, this analysis supports the current set of case 
definitions and the 2015 WHO guideline as appropriate tools for referral and treatment among 
those refusing referral. 
One of the most notable findings of the primary ANISA etiology study was Ureaplasma 
as the second most prevalent pathogen identified in this neonatal population.   Ureaplasma has 
not been identified previously as a relevant pathogen for this age group, and the currently 
recommended regimens (typically gentamicin or amoxicillin) would not be effective against this 
agent, as Ureaplasma infection typically include macrolides or tetracyclines. 59 The description 
of the infant population with Ureaplasma attributed illness highlighted how different this 
population is from infants with Ureaplasma illness described previously in the literature.  Given 
the severity of illness among infants in the Ureaplasma attributable population, either due the 
fact that Ureaplasma causes severe disease, or infants with Ureaplasma attributable illness had 
more severe outcomes due to treatment with antibiotics that are not effective against this agent, 
the fact that Ureaplasma is present in term infants, coupled with the complex media 
requirements that precluded growth on culture, and the fact that we did not identify another 
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viable explanation for the Ureaplasma finding, it is plausible to suggest that Ureaplasma has 
been under-detected in previous etiology studies. 
Additional research into Ureaplasma’s role in etiology of neonatal illness is needed, 
while being mindful of the unique requirements for diagnostics to accurately detect presence of 
this bacteria.  Further research into Ureaplasma as a causative agent of illness in neonates, as 
well as the relationship between the presence of Ureaplasma with preterm and low birthweight 
status, would inform whether changes to current antibiotic regimens recommended by WHO for 
treatment of ill neonates are needed. 
Lastly, improved diagnostics are key to further understanding causes of illness in 
neonates.  Better point of care diagnostics for a range of pathogens need to be developed, and 
more awareness of Ureaplasma as a potential etiologic agent of illness in term and preterm 
neonates among clinicians is needed to ensure current appropriate diagnostics are utilized.  From 
the methodologic perspective, better diagnostics for Bayesian pLCM methods should be 
developed to ensure precise and unbiased estimates are generated using these methods in a range 















APPENDIX 2. OVERALL MOLECULAR POLYMERASE CHAIN REACTION DETECTIONS BY TAQMAN ARRAY 
CARDS (TAC) OF SEPSIS PATHOGENS AMONG INFANTS WITH POSSIBLE SERIOUS INFECTION BY CASE 
DEFINITION, AETIOLOGY OF NEWBORN INFECTIONS IN SOUTH ASIA (ANISA) STUDY, 2011-14 
 Critically Ill2 Clinical severe infection3 






































Number tested N = 977 N = 1893 N = 747 N = 1717 N = 3971 N = 1893 N = 3255 N = 1717 
Pathogen  
Adenovirus 14 (1.4) 34(1.8) 0.8    58 (1.5) 34(1.8) 0.8    
Bordetella sp. 25 (2.6) 73(3.9) 0.7    203 (5.1) 73(3.9) 1.3    
Chlamydia 
pneumoniae 
1 (0.1) 3(0.2) 0.5    9 (0.2) 3(0.2) 1.0    
Chlamydia 
trachomatis 
2 (0.2) 5(0.3) 0.7    10 (0.3) 5(0.3) 1.0    
Cytomegalovirus 87 (9.4) 153(8.5) 1.1    245(6.8) 153(8.5) 0.8    
Escherichia coli 336(34.4) 461(24.4) 1.4 19 (2.5) 32(1.9) 0.5 958 (24.1) 461(24.4) 1.0 52 (1.6) 32(1.9) 0.8 
Influenza A 12 (1.2) 13(0.7) 1.7    39 (1.0) 13(0.7) 1.4    
Influenza B 2 (0.2) 3(0.2) 1.0    29 (0.7) 3(0.2) 3.5    
group A 
Streptococcus 
   2 (0.3) 0(0) /    12 (0.4) 0(0) / 
group B 
Streptococcus 
92 (9.4) 123(6.5) 1.4 7 (0.9) 6(0.4) 2.3 309 (7.8) 123(6.5) 1.2 11 (0.3) 6(0.4) 0.8 
Haemophilus 
influenzae 
   10 (1.3) 6(0.4) 3.3    25 (0.8) 6(0.4) 2.0 
Human 
metapneumovirus 
1 (0.1) 6(0.3) 0.3    20 (0.5) 6(0.3) 1.7    
Human parechovirus 2 (0.2) 12(0.6) 0.3    13 (0.3) 12(0.6) 0.5    
Klebsiella 
pneumoniae 
274(28.1) 422(22.3) 1.3 24 (3.2) 33(1.9) 1.7 817 (20.1) 422(22.3) 0.9 51 (1.6) 33(1.9) 0.8 
Mycoplasma 
pneumoniae 
1 (0.1) 1(0.1) 1.0    9 (0.2) 1(0.1) 2.0    
Neisseria 
meningitidis 
   3 (0.4) 4(0.2) 2.0    4 (0.1) 4(0.2) 0.5 
Parainfluenza virus 
type 1 
2 (0.2) 7(0.4) 0.5    23 (0.6) 7(0.4) 1.5    
Parainfluenza virus 
type 2 
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8 (0.8) 16(0.6) 1.3    51 (1.3) 16(0.6) 2.2    
Pseudomonas 
aeruginosa 
   6 (0.8) 7(0.4) 2.0    13 (0.4) 7(0.4) 1.0 
Respiratory syncytial 
virus 
62 (6.4) 25(1.3) 4.9    331 (8.3) 25(1.3) 6.4    
Rhinovirus / 
Enterovirus 
223(22.8) 644(34.0) 0.7 24 (3.2) 49(2.9) 1.1 1185(29.8) 644(34.0) 0.9 105 (3.2) 49(2.9) 1.1 
Rubella 5 (0.5) 5(0.3) 1.7    15 (0.4) 5(0.3) 1.3    
Salmonella sp.    14 (1.9) 30(1.8) 1.1    60 (1.8) 30(1.8) 1.0 
Staphylococcus 
aureus 
   8 (1.1) 15(0.9) 1.2    21 (0.7) 15(0.9) 0.8 
Streptococcus 
pneumoniae 
286(29.3) 628(33.2) 0.9 16 (2.1) 20(1.2) 1.75 1436(36.2) 628(33.2) 1.1 44 (1.4) 20(1.2) 1.2 
Ureaplasma sp. 152(15.6) 118(6.2) 2.5 3 (0.4) 6(0.4) 1.0 397(10.0) 118(6.2) 1.6 14 (0.4) 6(0.4) 1.0 
 
 Bangladesh Isolated Fast Breathing 4 




















Number tested N = 1161 N = 412 N = 847 N = 344 
Pathogen  
Adenovirus 16 (1.4) 12(2.9) 0.5    
Bordetella sp. 12 (1.0) 6(1.5) 0.7    
Chlamydia pneumoniae 1 (0.9) 2(0.5) 1.8    
Chlamydia trachomatis 3 (0.3) 1(0.2) 1.5    
Cytomegalovirus 82 (8.1) 44(12.3) 0.7    
Escherichia coli 430(37.0) 123(29.9) 1.2 15 (1.8) 11(3.2) 0.6 
Influenza A 10 (0.9) 3(0.7) 1.3    
Influenza B 6 (0.5) 0(0) /    
group A Streptococcus    3 (0.4) 0(0) / 
group B Streptococcus 239 (20.6) 74(18.0) 1.1 4 (0.5) 6(1.7) 0.3 
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Number tested N = 1161 N = 412 N = 847 N = 344 
Pathogen  
Human metapneumovirus 11 (1.0) 1(0.2) 5.0    
Human parechovirus 7 (0.6) 5(1.2) 0.5    
Klebsiella pneumoniae 308 (26.5) 101(24.5) 1.1 45 (5.3) 22(6.4) 0.8 
Mycoplasma pneumoniae 2 (0.2) 0(0) /    
Neisseria meningitidis    1 (0.1) 2(0.6) 0.2 
Parainfluenza virus type 1 3 (0.3) 4(1.0) 0.3    
Parainfluenza virus type 2 2 (0.2) 2(0.5) 0.4    
Parainfluenza virus type 3 14 (1.2) 6(1.5) 0.8    
Pseudomonas aeruginosa    2 (0.2) 3(0.9) 0.2 
Respiratory syncytial virus 43 (3.7) 3(0.7) 5.3    
Rhinovirus / Enterovirus 419(36.1) 190(46.1) 0.8 12 (1.4) 6(1.7) 0.8 
Rubella 5 (0.4) 1(0.2) 2.0    
Salmonella sp.    21 (2.5) 8(2.3) 1.1 
Staphylococcus aureus    6 (0.7) 10(2.9) 0.2 
Streptococcus pneumoniae 593 (51.1) 248(60.2) 0.8 9 (1.1) 10(2.9) 0.4 
Ureaplasma sp. 117 (10.1) 42(10.2) 1.0 2 (0.2) 2(0.6) 0.3 
1NP/OP=Nasopharyngeal/oropharyngeal 
2Critically Ill: NP/OP TAC: Number of ill infants tested for Cytomegalovirus N = 929; Number of healthy infants tested for Cytomegalovirus N = 1800; Blood TAC: Number of ill 
infants tested for Neisseria meningitidis N = 744 
3Clinical severe infection: NP/OP TAC: Number of ill infants tested for Cytomegalovirus N = 3580; Number of healthy infants tested for Cytomegalovirus N = 1800; Number of 
ill infants tested for Neisseria meningitidis N = 3238 
4Bangladesh Isolated Fast Breathing: NP/OP TAC: Number of ill infants tested for Cytomegalovirus N = 1013; Number of healthy infants tested for Cytomegalovirus N = 357; 
Number of ill infants tested for Neisseria meningitidis N = 844 
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APPENDIX 3. LIST OF PATHOGENS TESTED BY TAQMAN LOW DENSITY ARRAY 
(TAC) MOLECULAR PLATFORMS, BY TYPE OF SPECIMEN AVAILABLE FOR 
TEST, AETIOLOGY OF NEONATAL INFECTIONS IN SOUTH ASIA (ANISA) STUDY 
SITES, 2011-14   
Pathogen Type of specimen available for 
molecular test 
E. coli/Shigella both 
Enterovirus both 
Group B Streptococcus both 
Klebsiella pneumoniae both 
Streptococcus pneumoniae both 
Ureaplasma spp. both 
Neisseria meningitidis blood 
Pseudomonas aeruginosa blood 
pan-Salmonella blood 
Staphylococcus aureus blood 
Group A Streptococcus blood 
pan-Haemophilus influenzae blood 
Human metapneumovirus respiratory 
Adenovirus respiratory 
Cytomegalovirus respiratory 
Influenza A respiratory 
Influenza B respiratory 
Parainfluenza virus 1 respiratory 
Parainfluenza virus 2 respiratory 
Parainfluenza virus 3 respiratory 
Rubella respiratory 
Rhinovirus respiratory 
Mycoplasma pneumoniae respiratory 
Chlamydia trachomatis respiratory 
Chlamydia pneumoniae respiratory 
Bordetella pertussis I respiratory 
Respiratory syncytial virus respiratory 




APPENDIX 4. PATHOGENS ISOLATED FROM BLOOD CULTURE AMONG 
INFANTS WITH POSSIBLE SERIOUS INFECTION IN BANGLADESH, BY AGE OF 
ONSET AND CASE DEFINITION, AETIOLOGY OF NEONATAL INFECTIONS IN 
SOUTH ASIA (ANISA) STUDY, 2011-14   





















Subtotal gram positive 9 3 6 0 18 
  Enterococcus faecium      
  group A Streptococcus 1 3 3  7 
  group B Streptococcus 5    5 
  Staphylococcus aureus   1  1 
  Streptococcus oralis 1    1 
  Streptococcus pneumoniae 2  2  4 
Subtotal gram negative 4 1 8 1 14 
  Acinetobacter      
  Burkholderia cepacia      
  Citrobacter koseri      
  Edwardsiella tarda   1  1 
  Enterobacter sakazakii    1 1 
  Escherichia coli 2 1 2  5 
  Klebsiella pneumoniae 1    1 
  Morganella morganii   1  1 
  Neisseria meningitidis   4  4 
  Proteus mirabilis      
  Pseudomonas pseudomallei  1    1 
  Salmonella enterica      
  Serratia marcescens       
Total 13 4 14 1 32 
1 Early onset is defined as < 3 days of life  




APPENDIX 5. PATHOGENS ISOLATED FROM BLOOD CULTURE AMONG 
INFANTS MEETING THE CRITICALLY ILL AND CRITICAL SEVERE INFECTION 
CASE DEFINITIONS, AETIOLOGY OF NEONATAL INFECTIONS IN SOUTH ASIA 
(ANISA) STUDY, 2011-14   
Pathogen 
Critically Ill Infant 
(N=992) 
Clinical Severe Infection 
(N=4000) 
Total 
Subtotal gram positive 9 26 35 
  Enterococcus faecium 1  1 
  group A Streptococcus  11 11 
  group B Streptococcus 2 4 6 
  Staphylococcus aureus 4 8 12 
  Streptococcus oralis   0 
  Streptococcus   
  pneumoniae 
2 3 5 
Subtotal gram negative 29 34 63 
  Acinetobacter 2 1 3 
  Burkholderia cepacia 1 1 2 
  Citrobacter koseri  1 1 
  Edwardsiella tarda 1  1 
  Enterobacter sakazakii 2 1 3 
  Escherichia coli 7 13 20 
  Klebsiella pneumoniae 10 6 16 
  Morganella morganii  1 1 
  Neisseria meningitidis 1 4 5 
  Plesiomonas shigelloides  1 1 
  Proteus mirabilis  1 1 
  Pseudomonas aeruginosa 1  1 
  Pseudomonas  
  pseudomallei  
2 1 3 
  Salmonella enterica  2 2 
  Serratia marcescens  2 1 3 





APPENDIX 6. ESTIMATES FROM A PARTIAL LATENT CLASS MODEL OF THE 
PREVALENCE OF PATHOGENS CAUSING POSSIBLE SERIOUS BACTERIAL 
INFECTION, AETIOLOGY OF NEONATAL INFECTIONS IN SOUTH ASIA (ANISA) 
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